The	O
role	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
signaling	O
in	O
activated	O
DRA	B-DNA
transcription	O
.	O

Expression	O
of	O
human	B-DNA
MHC	I-DNA
HLA-DRA	I-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
can	O
be	O
up-regulated	O
in	O
B	B-cell_type
cells	I-cell_type
by	O
Ig	O
cross-linking	O
as	O
well	O
as	O
by	O
phorbol	O
esters	O
such	O
as	O
12-O-tetradecanoyl	O
phorbol	O
13-acetate	O
(	O
TPA	O
)	O
.	O

Induced	O
DRA	B-DNA
expression	O
involves	O
activation	O
of	O
restricted	B-protein
protein	I-protein
kinase	I-protein
C	I-protein
(	I-protein
PKC	I-protein
)	I-protein
isoforms	I-protein
,	O
resulting	O
in	O
activated	O
activator	O
protein-1	B-protein
-dependent	O
transcription	O
.	O

In	O
this	O
report	O
expression	O
profiles	O
and	O
activation	O
of	O
PKC	B-protein
were	O
analyzed	O
in	O
human	B-cell_line
Raji	I-cell_line
B	I-cell_line
lymphoblastoid	I-cell_line
cells	I-cell_line
.	O

Transient	O
transfection	O
analysis	O
with	O
target	B-DNA
plasmids	I-DNA
containing	O
either	O
DRA	B-DNA
promoter	I-DNA
(	O
wild-type	O
or	O
mutated	O
)	O
or	O
TPA	B-DNA
response	I-DNA
elements	I-DNA
demonstrated	O
that	O
pretreatment	O
with	O
the	O
selective	O
PKC	B-protein
inhibitor	O
GF	O
109203X	O
repressed	O
TPA-mediated	O
activation	O
.	O

Western	O
analysis	O
performed	O
on	O
cellular	O
fractions	O
of	O
resting	B-cell_type
cells	I-cell_type
and	O
of	O
TPA-activated	B-cell_type
cells	I-cell_type
revealed	O
abundant	O
expression	O
of	O
classical	B-protein
PKC-alpha	I-protein
(	O
cPKC-alpha	B-protein
)	O
,	O
cPKC-betaII	B-protein
,	O
and	O
atypical	B-protein
PKC-zeta	I-protein
isoforms	I-protein
and	O
identified	O
a	O
sustained	O
translocation	O
of	O
cPKC-alpha	B-protein
and	O
cPKC-betaII	B-protein
from	O
the	O
cytosolic	O
compartment	O
to	O
membranes	O
.	O

As	O
expected	O
,	O
the	O
distribution	O
of	O
atypical	B-protein
PKC-zeta	I-protein
was	O
unaffected	O
by	O
TPA	O
treatment	O
and	O
displayed	O
an	O
even	O
distribution	O
between	O
cytosol	O
and	O
membranes	O
.	O

This	O
finding	O
was	O
confirmed	O
by	O
immunofluorescence	O
microscopy	O
.	O

The	O
TPA-mediated	O
translocation	O
of	O
cPKC-alpha	B-protein
and	O
cPKC-betaII	B-protein
was	O
not	O
influenced	O
by	O
pretreatment	O
with	O
GF	O
109203X	O
.	O

Finally	O
,	O
functional	O
activation	O
and	O
translocation	O
of	O
PKC	B-protein
were	O
investigated	O
with	O
a	O
selective	O
in	O
vitro	O
kinase	O
assay	O
.	O

Together	O
,	O
these	O
results	O
show	O
that	O
activated	O
HLA-DRA	B-protein
expression	O
in	O
response	O
to	O
TPA	O
treatment	O
is	O
strictly	O
dependent	O
on	O
PKC	B-protein
activation	O
acting	O
on	O
the	O
X2	B-DNA
box	I-DNA
of	O
the	O
DRA	B-DNA
promoter	I-DNA
and	O
that	O
selective	O
inhibition	O
of	O
PKC	B-protein
enzymatic	O
activity	O
does	O
not	O
influence	O
subcellular	O
localization	O
of	O
expressed	O
PKC	B-protein
isoenzymes	I-protein
.	O

Thus	O
,	O
the	O
translocation	O
event	O
per	O
se	O
occurs	O
independently	O
of	O
PKC	B-protein
activation	O
in	O
these	O
cells	O
.	O

2	NULL
:	NULL
``	NULL
Lr	NULL
‘	NULL
W	NULL
e	NULL
a	NULL
3	NULL
g	NULL
?	NULL

_-	NULL
.	NULL

_	NULL
The	NULL
Attune	NULL
``	NULL
NXT	NULL
Flow	NULL
Cytometer	NULL
system	NULL
___	NULL
Let	NULL
's	NULL
get	NULL
to	NULL
the	NULL
science	NULL
oo	NULL
,	NULL
|	NULL
invitrogen	NULL
The	NULL
Role	NULL
of	NULL
Protein	NULL
Kinase	NULL
C	NULL
Signaling	NULL
in	NULL
f	NULL
~	NULL
*A	NULL
The	NULL
10	NULL
“	NULL
Alggﬁaélo	NULL
gy	NULL
Activated	NULL
DRA	NULL
Transcription	NULL
Niclas	NULL
Setterblad	NULL
,	NULL
Isaac	NULL
Onyango	NULL
,	NULL
Ulla	NULL
Pihlgren	NULL
,	NULL
Lars	NULL
Rask	NULL
fe	NULL
200.	NULL
and	NULL
Goran	NULL
Andersson	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

J	NULL
Immunol	NULL
1998	NULL
;	NULL
161:4819-4824	NULL
;	NULL
;	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/161/9/4819	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
42	NULL
articles	NULL
,	NULL
22	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/161/9/4819.full	NULL
#	NULL
ref-list-	NULL
1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Role	NULL
of	NULL
Protein	NULL
Kinase	NULL
C	NULL
Signaling	NULL
in	NULL
Activated	NULL
DRA	NULL
Transcription	NULL
'	NULL
Niclas	NULL
Setterblad	NULL
,	NULL
``	NULL
*	NULL
Isaac	NULL
Onyango	NULL
,	NULL
``	NULL
Ulla	NULL
Pihlgren	NULL
,	NULL
*	NULL
Lars	NULL
Rask	NULL
,	NULL
``	NULL
and	NULL
Goran	NULL
Expression	NULL
of	NULL
human	NULL
MHC	NULL
HLA-DARA	NULL
class	NULL
II	NULL
gene	NULL
can	NULL
be	NULL
up-regulated	NULL
in	NULL
B	NULL
cells	NULL
by	NULL
Ig	NULL
cross-linking	NULL
as	NULL
well	NULL
as	NULL
by	NULL
phorbol	NULL
esters	NULL
such	NULL
as	NULL
12-O-tetradecanoyl	NULL
phorbol	NULL
13-acetate	NULL
(	NULL
TPA	NULL
)	NULL
.	NULL

Induced	NULL
DRA	NULL
expression	NULL
involves	NULL
activation	NULL
of	NULL
restricted	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
isoforms	NULL
,	NULL
resulting	NULL
in	NULL
activated	NULL
activator	NULL
protein-1-dependent	NULL
transcription	NULL
.	NULL

In	NULL
this	NULL
report	NULL
expression	NULL
profiles	NULL
and	NULL
activation	NULL
of	NULL
PKC	NULL
were	NULL
analyzed	NULL
in	NULL
human	NULL
Raji	NULL
B	NULL
lymphoblastoid	NULL
cells	NULL
.	NULL

Transient	NULL
transfection	NULL
analysis	NULL
with	NULL
target	NULL
plasmids	NULL
containing	NULL
either	NULL
DRA	NULL
promoter	NULL
(	NULL
wild-type	NULL
or	NULL
mutated	NULL
)	NULL
or	NULL
TPA	NULL
response	NULL
elements	NULL
demonstrated	NULL
that	NULL
pretreatment	NULL
with	NULL
the	NULL
selective	NULL
PKC	NULL
inhibitor	NULL
GF	NULL
109203X	NULL
repressed	NULL
TPA-mediated	NULL
activation	NULL
.	NULL

Western	NULL
analysis	NULL
performed	NULL
on	NULL
cellular	NULL
fractions	NULL
of	NULL
resting	NULL
cells	NULL
and	NULL
of	NULL
TPA-activated	NULL
cells	NULL
revealed	NULL
abundant	NULL
expression	NULL
of	NULL
classical	NULL
PKC-a	NULL
(	NULL
cPKC-a	NULL
@	NULL
)	NULL
,	NULL
cPKC-BII	NULL
,	NULL
and	NULL
atypical	NULL
PKC-¢	NULL
isoforms	NULL
and	NULL
identified	NULL
a	NULL
sustained	NULL
translocation	NULL
of	NULL
and	NULL
cPKC-BII	NULL
from	NULL
the	NULL
cytosolic	NULL
compartment	NULL
to	NULL
membranes	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
the	NULL
distribution	NULL
of	NULL
atypical	NULL
PKC-Z	NULL
was	NULL
unaffected	NULL
by	NULL
TPA	NULL
treatment	NULL
and	NULL
displayed	NULL
an	NULL
even	NULL
distribution	NULL
between	NULL
cytosol	NULL
and	NULL
membranes	NULL
.	NULL

This	NULL
finding	NULL
was	NULL
confirmed	NULL
by	NULL
immunofluorescence	NULL
microscopy	NULL
.	NULL

The	NULL
TPA-mediated	NULL
translocation	NULL
of	NULL
cPKC-a	NULL
«	NULL
and	NULL
cPKC-BIL	NULL
was	NULL
not	NULL
influenced	NULL
by	NULL
pretreatment	NULL
with	NULL
GF	NULL
109203X	NULL
.	NULL

Finally	NULL
,	NULL
functional	NULL
activation	NULL
and	NULL
translocation	NULL
of	NULL
PKC	NULL
were	NULL
investigated	NULL
with	NULL
a	NULL
selective	NULL
in	NULL
vitro	NULL
kinase	NULL
assay	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
results	NULL
show	NULL
that	NULL
activated	NULL
HLA-DRA	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
TPA	NULL
treatment	NULL
is	NULL
strictly	NULL
dependent	NULL
on	NULL
PKC	NULL
activation	NULL
acting	NULL
on	NULL
the	NULL
X2	NULL
box	NULL
of	NULL
the	NULL
DRA	NULL
promoter	NULL
and	NULL
that	NULL
selective	NULL
inhibition	NULL
of	NULL
PKC	NULL
enzymatic	NULL
activity	NULL
does	NULL
not	NULL
influence	NULL
subcellular	NULL
localization	NULL
of	NULL
expressed	NULL
PKC	NULL
isoenzymes	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
translocation	NULL
event	NULL
per	NULL
se	NULL
occurs	NULL
independently	NULL
of	NULL
PKC	NULL
activation	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

ell	NULL
signaling	NULL
events	NULL
mediated	NULL
via	NULL
membrane-associated	NULL
Ag	NULL
receptor	NULL
Igs	NULL
is	NULL
an	NULL
important	NULL
regulatory	NULL
pathway	NULL
for	NULL
B	NULL
cell	NULL
activation	NULL
and	NULL
development	NULL
(	NULL
for	NULL
review	NULL
,	NULL
see	NULL
Ref	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Normally	NULL
,	NULL
this	NULL
activation	NULL
is	NULL
mediated	NULL
via	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
by	NULL
the	NULL
src	NULL
family	NULL
of	NULL
kinases	NULL
,	NULL
phosphoinositide	NULL
turnover	NULL
mediated	NULL
by	NULL
phospholipase	NULL
C	NULL
and	NULL
phosphatidylinositol	NULL
3-kinase	NULL
(	NULL
PI-3	NULL
kinase	NULL
)	NULL
,	NULL
*	NULL
as	NULL
well	NULL
as	NULL
activation	NULL
of	NULL
the	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
family	NULL
of	NULL
serine/threonine	NULL
kinases	NULL
(	NULL
2-5	NULL
)	NULL
.	NULL

An	NULL
important	NULL
nuclear	NULL
event	NULL
triggered	NULL
by	NULL
PKC	NULL
signaling	NULL
in	NULL
B	NULL
cells	NULL
is	NULL
the	NULL
stimulation	NULL
of	NULL
activator	NULL
protein	NULL
1	NULL
(	NULL
AP-1	NULL
)	NULL
-dependent	NULL
gene	NULL
expression	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
.	NULL

Receptor-activated	NULL
phospholipase	NULL
C	NULL
enzymatically	NULL
breaks	NULL
down	NULL
phosphatidyl	NULL
4,5-bisphosphate	NULL
into	NULL
1,2-diacylglycerol	NULL
(	NULL
DAG	NULL
)	NULL
and	NULL
inositol	NULL
1,4,5-triphosphate	NULL
.	NULL

Both	NULL
these	NULL
components	NULL
are	NULL
subsequently	NULL
involved	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
PKC	NULL
.	NULL

Inositol	NULL
1,4,5-triphos-phate	NULL
causes	NULL
the	NULL
release	NULL
of	NULL
Ca**	NULL
from	NULL
intracellular	NULL
stores	NULL
,	NULL
and	NULL
DAG	NULL
is	NULL
a	NULL
potent	NULL
activator	NULL
of	NULL
PKC	NULL
signal	NULL
transduction	NULL
by	NULL
direct	NULL
binding	NULL
to	NULL
the	NULL
regulatory	NULL
C1	NULL
domain	NULL
of	NULL
PKC	NULL
(	NULL
2	NULL
,	NULL
8	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
*Uppsala	NULL
Genetic	NULL
Center	NULL
,	NULL
Swedish	NULL
University	NULL
of	NULL
Agricultural	NULL
Sciences	NULL
,	NULL
and	NULL
*Depart-ment	NULL
of	NULL
Medical	NULL
Biochemistry	NULL
and	NULL
Microbiology	NULL
,	NULL
Biomedical	NULL
Center	NULL
,	NULL
Uppsala	NULL
Uni-versity	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
Received	NULL
for	NULL
publication	NULL
February	NULL
5	NULL
,	NULL
1998	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
July	NULL
1	NULL
,	NULL
1998	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Ake	NULL
Wiberg	NULL
Foundation	NULL
,	NULL
the	NULL
Swedish	NULL
Cancer	NULL
Society	NULL
,	NULL
and	NULL
the	NULL
Swedish	NULL
Medical	NULL
Research	NULL
Council	NULL
.	NULL

2	NULL
Current	NULL
address	NULL
:	NULL
Laboratoire	NULL
de	NULL
Transfert	NULL
Genetique	NULL
et	NULL
d'Oncologie	NULL
,	NULL
Institute	NULL
of	NULL
Hematology	NULL
,	NULL
Hopital	NULL
Saint-Louis	NULL
,	NULL
F-75475	NULL
Paris	NULL
,	NULL
France	NULL
.	NULL

3	NULL
Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Goran	NULL
Andersson	NULL
,	NULL
BioTrans-plant	NULL
Inc.	NULL
,	NULL
Building	NULL
75	NULL
,	NULL
3rd	NULL
Avenue	NULL
,	NULL
Charlestown	NULL
Navy	NULL
Yard	NULL
,	NULL
Charlestown	NULL
,	NULL
MA	NULL
02129	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
goran.andersson	NULL
@	NULL
biotransplant.com	NULL
*	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
PI-3	NULL
kinase	NULL
,	NULL
phosphatidylinositol	NULL
3-	NULL
kinase	NULL
;	NULL
PKC	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
;	NULL
AP-1	NULL
,	NULL
activator	NULL
protein-1	NULL
;	NULL
DAG	NULL
,	NULL
1,2-diacylglycerol	NULL
;	NULL
TPA	NULL
,	NULL
12-O-tetradecanoy1	NULL
phorbol	NULL
13-acetate	NULL
;	NULL
cPKC	NULL
,	NULL
classical	NULL
protein	NULL
kinase	NULL
C	NULL
;	NULL
nPKC	NULL
,	NULL
novel	NULL
protein	NULL
kinase	NULL
C	NULL
;	NULL
aPKC	NULL
,	NULL
atypical	NULL
protein	NULL
kinase	NULL
C	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyl-transferase	NULL
;	NULL
TRE	NULL
,	NULL
TPA	NULL
response	NULL
element	NULL
.	NULL

Copyright	NULL
©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
1998	NULL
,	NULL
161	NULL
;	NULL
4819-4824.	NULL
cells	NULL
with	NULL
tumor-promoting	NULL
phorbol	NULL
esters	NULL
bypasses	NULL
the	NULL
need	NULL
for	NULL
activation	NULL
of	NULL
PKC	NULL
by	NULL
phosphoinositide	NULL
breakdown	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

PI-3	NULL
kinase	NULL
catalyzes	NULL
the	NULL
phosphorylation	NULL
of	NULL
phosphatidylinositol	NULL
4,5-bisphosphate	NULL
,	NULL
giving	NULL
rise	NULL
to	NULL
phosphatidylinositol	NULL
3,4,5-triphos-phate	NULL
,	NULL
which	NULL
is	NULL
a	NULL
putative	NULL
second	NULL
messenger	NULL
for	NULL
the	NULL
atypical	NULL
PKC	NULL
isoforms	NULL
(	NULL
see	NULL
below	NULL
)	NULL
(	NULL
5	NULL
)	NULL
.	NULL

In	NULL
a	NULL
recent	NULL
report	NULL
,	NULL
12-O-tetradecanoyl	NULL
phorbol	NULL
13-acetate	NULL
(	NULL
TPA	NULL
)	NULL
was	NULL
shown	NULL
to	NULL
induce	NULL
PI-3	NULL
kinase	NULL
activity	NULL
by	NULL
itself	NULL
.	NULL

Further	NULL
,	NULL
TPA	NULL
and	NULL
PI-3	NULL
kinase	NULL
were	NULL
shown	NULL
to	NULL
act	NULL
syner-gistically	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Following	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
phorbol	NULL
esters	NULL
,	NULL
they	NULL
are	NULL
persistently	NULL
present	NULL
in	NULL
the	NULL
plasma	NULL
membrane	NULL
and	NULL
mimic	NULL
the	NULL
action	NULL
of	NULL
DAG	NULL
(	NULL
12	NULL
)	NULL
.	NULL

PKC	NULL
's	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
play	NULL
key	NULL
roles	NULL
in	NULL
a	NULL
multitude	NULL
of	NULL
cellular	NULL
responses	NULL
,	NULL
including	NULL
regulation	NULL
of	NULL
gene	NULL
expression	NULL
,	NULL
influences	NULL
on	NULL
the	NULL
cytoskeleton	NULL
,	NULL
cell	NULL
growth	NULL
,	NULL
and	NULL
differentiation	NULL
(	NULL
2	NULL
)	NULL
.	NULL

To	NULL
date	NULL
,	NULL
>	NULL
12	NULL
distinct	NULL
PKC	NULL
isoenzymes	NULL
have	NULL
been	NULL
identified	NULL
.	NULL

Based	NULL
on	NULL
their	NULL
sequence	NULL
similarities	NULL
and	NULL
function	NULL
they	NULL
have	NULL
been	NULL
divided	NULL
into	NULL
three	NULL
families	NULL
:	NULL
1	NULL
)	NULL
classical	NULL
(	NULL
cPKC	NULL
)	NULL
,	NULL
including	NULL
cPKC-	NULL
@	NULL
,	NULL
-BI	NULL
,	NULL
-B	NULL
,	NULL
and	NULL
-y	NULL
;	NULL
cPKC-fI	NULL
and	NULL
-BII	NULL
arise	NULL
by	NULL
alternative	NULL
splicing	NULL
,	NULL
resulting	NULL
in	NULL
distinct	NULL
carboxyl-terminal	NULL
regions	NULL
;	NULL
2	NULL
)	NULL
novel	NULL
(	NULL
aPKC	NULL
)	NULL
,	NULL
comprising	NULL
nPKC-8	NULL
,	NULL
-€	NULL
,	NULL
-€	NULL
'	NULL
,	NULL
-7	NULL
,	NULL
-0	NULL
,	NULL
and	NULL
-u	NULL
;	NULL
nPKC-e	NULL
and	NULL
-e	NULL
'	NULL
represent	NULL
two	NULL
splice	NULL
variants	NULL
;	NULL
and	NULL
finally	NULL
,	NULL
3	NULL
)	NULL
atypical	NULL
(	NULL
aPKC	NULL
)	NULL
,	NULL
aPKC-Z	NULL
and	NULL
aPKC-i	NULL
.	NULL

The	NULL
cPKC	NULL
isoforms	NULL
are	NULL
dependent	NULL
on	NULL
calcium	NULL
and	NULL
phospholipids	NULL
,	NULL
whereas	NULL
the	NULL
nPKCs	NULL
are	NULL
calcium	NULL
independent	NULL
(	NULL
for	NULL
reviews	NULL
,	NULL
see	NULL
Refs	NULL
.	NULL

2	NULL
and	NULL
13-15	NULL
)	NULL
.	NULL

Both	NULL
cPKC	NULL
and	NULL
nPKC	NULL
isoforms	NULL
are	NULL
activated	NULL
by	NULL
phorbol	NULL
esters	NULL
(	NULL
16	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
aPKCs	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
unresponsive	NULL
to	NULL
phorbol	NULL
esters	NULL
and	NULL
DAG	NULL
,	NULL
and	NULL
their	NULL
exact	NULL
mode	NULL
of	NULL
activation	NULL
is	NULL
largely	NULL
unknown	NULL
.	NULL

However	NULL
,	NULL
it	NULL
was	NULL
recently	NULL
reported	NULL
that	NULL
aPKC-+	NULL
appears	NULL
to	NULL
be	NULL
activated	NULL
by	NULL
PI-3	NULL
kinase	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Hence	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
most	NULL
PKC	NULL
isoforms	NULL
are	NULL
dependent	NULL
on	NULL
phosphoinositide	NULL
breakdown	NULL
mediated	NULL
through	NULL
either	NULL
receptor	NULL
tyrosine	NULL
kinase	NULL
or	NULL
G	NULL
protein-coupled	NULL
re-ceptor-stimulated	NULL
activation	NULL
pathways	NULL
.	NULL

Treatment	NULL
of	NULL
cells	NULL
with	NULL
phorbol	NULL
esters	NULL
or	NULL
growth	NULL
factors	NULL
leads	NULL
to	NULL
translocation	NULL
of	NULL
some	NULL
PKC	NULL
isoforms	NULL
from	NULL
the	NULL
cytosol	NULL
to	NULL
the	NULL
membrane	NULL
and	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
PKC	NULL
activation	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

13	NULL
;	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

Extensive	NULL
characterization	NULL
of	NULL
PKC	NULL
has	NULL
revealed	NULL
that	NULL
different	NULL
cell	NULL
0022-1767/98/	NULL
$	NULL
02.00	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
4820	NULL
types	NULL
express	NULL
defined	NULL
sets	NULL
of	NULL
PKC	NULL
isoforms	NULL
that	NULL
are	NULL
differentially	NULL
localized	NULL
in	NULL
subcellular	NULL
compartments	NULL
(	NULL
15	NULL
,	NULL
20	NULL
)	NULL
.	NULL

Class	NULL
II	NULL
expression	NULL
in	NULL
B	NULL
cells	NULL
can	NULL
be	NULL
up-regulated	NULL
by	NULL
several	NULL
means	NULL
,	NULL
including	NULL
Ig	NULL
cross-linking	NULL
and	NULL
PKC	NULL
activation	NULL
.	NULL

Artificial	NULL
phorbol	NULL
ester	NULL
treatment	NULL
mimics	NULL
these	NULL
responses	NULL
,	NULL
and	NULL
the	NULL
induced	NULL
class	NULL
II	NULL
expression	NULL
involves	NULL
activation	NULL
of	NULL
restricted	NULL
PKC	NULL
isoforms	NULL
that	NULL
result	NULL
in	NULL
activated	NULL
AP-1-dependent	NULL
transcription	NULL
(	NULL
6	NULL
,	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
activated	NULL
HLA-DRA	NULL
transcription	NULL
is	NULL
dependent	NULL
on	NULL
PKC	NULL
signaling	NULL
in	NULL
Raji	NULL
B	NULL
cells	NULL
(	NULL
23	NULL
)	NULL
.	NULL

To	NULL
better	NULL
understand	NULL
the	NULL
molecular	NULL
mechanisms	NULL
underlying	NULL
this	NULL
activation	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
expression	NULL
profiles	NULL
and	NULL
functional	NULL
properties	NULL
of	NULL
PKC	NULL
isoforms	NULL
in	NULL
resting	NULL
and	NULL
TPA-activated	NULL
Raji	NULL
B	NULL
cells	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Cell	NULL
culture	NULL
and	NULL
treatment	NULL
The	NULL
human	NULL
B	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
Raji	NULL
(	NULL
24	NULL
)	NULL
(	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
,	NULL
Manassas	NULL
,	NULL
VA	NULL
;	NULL
CCL86	NULL
)	NULL
was	NULL
grown	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
8	NULL
%	NULL
CO	NULL
;	NULL
atmosphere	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
FCS	NULL
,	NULL
glutamine	NULL
,	NULL
100	NULL
IU/ml	NULL
penicillin	NULL
,	NULL
and	NULL
50	NULL
pg/ml	NULL
streptomycin	NULL
.	NULL

When	NULL
cells	NULL
attained	NULL
a	NULL
density	NULL
of	NULL
10°	NULL
cells/ml	NULL
,	NULL
150	NULL
ml	NULL
of	NULL
cells	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
~150	NULL
X	NULL
10°	NULL
cells	NULL
)	NULL
received	NULL
different	NULL
treatments	NULL
:	NULL
no	NULL
treatment	NULL
(	NULL
control	NULL
cells	NULL
)	NULL
,	NULL
10	NULL
nM	NULL
TPA	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
,	NULL
10	NULL
nM	NULL
TPA	NULL
after	NULL
a	NULL
15-min	NULL
preincubation	NULL
with	NULL
2	NULL
uM	NULL
GF	NULL
109203X	NULL
(	NULL
catalogue	NULL
no	NULL
.	NULL

203290-8	NULL
;	NULL
K	NULL
,	NULL
=	NULL
10	NULL
nM	NULL
;	NULL
Calbio-chem	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
and	NULL
10	NULL
M	NULL
TPA	NULL
.	NULL

Stock	NULL
solutions	NULL
of	NULL
TPA	NULL
and	NULL
GF	NULL
109203X	NULL
prepared	NULL
in	NULL
DMSO	NULL
were	NULL
used	NULL
.	NULL

After	NULL
24	NULL
h	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
,	NULL
and	NULL
used	NULL
for	NULL
protein	NULL
fraction	NULL
preparation	NULL
.	NULL

To	NULL
obtain	NULL
more	NULL
time	NULL
points	NULL
,	NULL
extracts	NULL
from	NULL
cells	NULL
treated	NULL
for	NULL
2	NULL
and	NULL
4	NULL
h	NULL
with	NULL
10	NULL
nM	NULL
TPA	NULL
were	NULL
prepared	NULL
for	NULL
use	NULL
in	NULL
the	NULL
PKC	NULL
assay	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

Transient	NULL
transfections	NULL
and	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
assays	NULL
Raji	NULL
B	NULL
cells	NULL
were	NULL
grown	NULL
exponentially	NULL
(	NULL
see	NULL
above	NULL
)	NULL
to	NULL
a	NULL
cell	NULL
density	NULL
of	NULL
10°	NULL
cells/ml	NULL
and	NULL
transfected	NULL
according	NULL
to	NULL
the	NULL
DEAE-dextran-chloroquine	NULL
bi-phosphate	NULL
technique	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Three	NULL
reporter	NULL
vectors	NULL
were	NULL
transfected	NULL
:	NULL
1	NULL
)	NULL
pDRASCAT	NULL
,	NULL
a	NULL
plasmid	NULL
containing	NULL
the	NULL
wild-type	NULL
DRA	NULL
promoter	NULL
from	NULL
positions	NULL
-150	NULL
to	NULL
+31	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
reporter	NULL
gene	NULL
(	NULL
pDRASCAT	NULL
)	NULL
(	NULL
26	NULL
)	NULL
;	NULL
2	NULL
)	NULL
pPXM	NULL
(	NULL
-93/-91	NULL
)	NULL
,	NULL
which	NULL
is	NULL
similar	NULL
to	NULL
pDRASCAT	NULL
but	NULL
contains	NULL
clustered	NULL
point	NULL
mutations	NULL
of	NULL
the	NULL
X2	NULL
box	NULL
from	NULL
positions	NULL
-93	NULL
to	NULL
-91	NULL
(	NULL
27	NULL
)	NULL
;	NULL
and	NULL
3	NULL
)	NULL
pTKCAT.3XAP1	NULL
,	NULL
which	NULL
contains	NULL
three	NULL
AP-1	NULL
sites	NULL
placed	NULL
upstream	NULL
of	NULL
the	NULL
minimal	NULL
heterologous	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Ten	NULL
micrograms	NULL
of	NULL
plasmid	NULL
DNA	NULL
was	NULL
used	NULL
in	NULL
each	NULL
transfection	NULL
;	NULL
transfections	NULL
were	NULL
performed	NULL
in	NULL
triplicate	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
allowed	NULL
to	NULL
recover	NULL
for	NULL
24	NULL
h.	NULL
The	NULL
transfected	NULL
cells	NULL
then	NULL
received	NULL
different	NULL
treatments	NULL
:	NULL
no	NULL
treatment	NULL
(	NULL
control	NULL
)	NULL
,	NULL
10	NULL
nM	NULL
TPA	NULL
,	NULL
and	NULL
10	NULL
nM	NULL
TPA	NULL
after	NULL
a	NULL
15-min	NULL
preincubation	NULL
with	NULL
2	NULL
M	NULL
GF	NULL
109203X	NULL
.	NULL

After	NULL
24	NULL
h	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
lysed	NULL
,	NULL
and	NULL
60	NULL
pg	NULL
of	NULL
proteins	NULL
were	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
at	NULL
37°C	NULL
for	NULL
12	NULL
h	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
29	NULL
)	NULL
.	NULL

CAT	NULL
enzymatic	NULL
activity	NULL
was	NULL
quantified	NULL
using	NULL
an	NULL
ImageQuant	NULL
PhosphorImager	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
,	NULL
Sunnyvale	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Preparation	NULL
of	NULL
soluble	NULL
and	NULL
particulate	NULL
protein	NULL
fractions	NULL
Soluble	NULL
and	NULL
particulate	NULL
protein	NULL
fractions	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
washed	NULL
in	NULL
PBS	NULL
,	NULL
then	NULL
lysed	NULL
in	NULL
a	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
EDTA	NULL
,	NULL
5	NULL
mM	NULL
EGTA	NULL
,	NULL
10	NULL
mM	NULL
2-ME	NULL
,	NULL
50	NULL
ug/ml	NULL
leupeptin	NULL
,	NULL
50	NULL
ug/ml	NULL
aprotinin	NULL
,	NULL
and	NULL
2	NULL
mM	NULL
PMSF	NULL
)	NULL
followed	NULL
by	NULL
centrifugation	NULL
at	NULL
100,000	NULL
x	NULL
g	NULL
for	NULL
30	NULL
min	NULL
.	NULL

The	NULL
supernatant	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
soluble	NULL
fraction	NULL
)	NULL
was	NULL
collected	NULL
,	NULL
and	NULL
the	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
the	NULL
same	NULL
buffer	NULL
containing	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
.	NULL

After	NULL
30-min	NULL
incubation	NULL
on	NULL
ice	NULL
,	NULL
the	NULL
suspension	NULL
was	NULL
centrifuged	NULL
as	NULL
described	NULL
above	NULL
to	NULL
obtain	NULL
the	NULL
Triton	NULL
X-100-soluble	NULL
fraction	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
particulate	NULL
fraction	NULL
)	NULL
.	NULL

Typically	NULL
,	NULL
8	NULL
mg	NULL
of	NULL
soluble	NULL
proteins	NULL
and	NULL
2	NULL
mg	NULL
of	NULL
particulate	NULL
proteins	NULL
were	NULL
obtained	NULL
from	NULL
approximately	NULL
10	NULL
``	NULL
cells	NULL
.	NULL

No	NULL
fluctuations	NULL
in	NULL
the	NULL
yield	NULL
could	NULL
be	NULL
related	NULL
to	NULL
any	NULL
of	NULL
the	NULL
treatments	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
determined	NULL
by	NULL
the	NULL
Bradford	NULL
assay	NULL
(	NULL
Bio-Rad	NULL
,	NULL
Hercules	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

When	NULL
used	NULL
for	NULL
the	NULL
PKC-specific	NULL
assay	NULL
,	NULL
the	NULL
protein	NULL
fractions	NULL
were	NULL
kept	NULL
on	NULL
ice	NULL
until	NULL
use	NULL
,	NULL
as	NULL
thawing/freezing	NULL
cycles	NULL
were	NULL
found	NULL
to	NULL
modify	NULL
PKC	NULL
activities	NULL
.	NULL

PKC	NULL
Abs	NULL
Rabbit	NULL
polyclonal	NULL
Abs	NULL
specific	NULL
for	NULL
PKC-a	NULL
,	NULL
-BII	NULL
,	NULL
-y	NULL
,	NULL
-8	NULL
,	NULL
-e	NULL
,	NULL
-	NULL
»	NULL
,	NULL
-0	NULL
,	NULL
and	NULL
-£	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

All	NULL
Abs	NULL
were	NULL
isoform	NULL
specific	NULL
,	NULL
except	NULL
for	NULL
anti-cPKC-	NULL
«	NULL
,	NULL
which	NULL
had	NULL
a	NULL
weak	NULL
cross-reactivity	NULL
with	NULL
PKC-BI	NULL
and	NULL
-BIL	NULL
ROLE	NULL
OF	NULL
PKC	NULL
IN	NULL
ACTIVATED	NULL
DRA	NULL
TRANSCRIPTION	NULL
Western	NULL
blotting	NULL
Two	NULL
hundred	NULL
micrograms	NULL
of	NULL
proteins	NULL
were	NULL
loaded	NULL
onto	NULL
single-well	NULL
10	NULL
%	NULL
SDS-PAGE	NULL
(	NULL
31	NULL
)	NULL
prepared	NULL
and	NULL
run	NULL
on	NULL
Mighty	NULL
Small	NULL
II	NULL
equipment	NULL
(	NULL
Hoefer	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Proteins	NULL
were	NULL
transferred	NULL
onto	NULL
nitrocellulose	NULL
filters	NULL
(	NULL
Hybond-C	NULL
Extra	NULL
,	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
by	NULL
semidry	NULL
electro-blotting	NULL
for	NULL
30	NULL
min	NULL
at	NULL
15	NULL
V	NULL
and	NULL
400	NULL
mA	NULL
.	NULL

Filters	NULL
were	NULL
incubated	NULL
for	NULL
20	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
50	NULL
mM	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
and	NULL
0.05	NULL
%	NULL
Tween	NULL
20	NULL
(	NULL
TBS-T	NULL
)	NULL
containing	NULL
5	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
fat-free	NULL
dried	NULL
milk	NULL
.	NULL

The	NULL
nitrocellulose	NULL
membranes	NULL
were	NULL
incubated	NULL
for	NULL
45	NULL
min	NULL
with	NULL
specific	NULL
Abs	NULL
against	NULL
PKC	NULL
isoforms	NULL
(	NULL
see	NULL
above	NULL
;	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
,	NULL
all	NULL
at	NULL
a	NULL
dilution	NULL
of	NULL
0.1	NULL
pg/ml	NULL
in	NULL
TBS-T	NULL
.	NULL

This	NULL
step	NULL
was	NULL
performed	NULL
with	NULL
a	NULL
Mighty	NULL
Small	NULL
Deca-Probe	NULL
incubation	NULL
manifold	NULL
(	NULL
Hoefer	NULL
)	NULL
.	NULL

After	NULL
washing	NULL
three	NULL
times	NULL
with	NULL
TBS-T	NULL
,	NULL
a	NULL
1/5000	NULL
dilution	NULL
of	NULL
horseradish	NULL
peroxidase-labeled	NULL
anti-rabbit	NULL
IgG	NULL
was	NULL
added	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
then	NULL
washed	NULL
three	NULL
times	NULL
in	NULL
TBS-T	NULL
and	NULL
once	NULL
in	NULL
TBS	NULL
,	NULL
and	NULL
the	NULL
blots	NULL
were	NULL
developed	NULL
using	NULL
enhanced	NULL
chemiluminescence	NULL
Western	NULL
blotting	NULL
reagents	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

To	NULL
check	NULL
for	NULL
reproducibility	NULL
,	NULL
the	NULL
blots	NULL
were	NULL
repeated	NULL
on	NULL
multiwell	NULL
gels	NULL
,	NULL
where	NULL
each	NULL
extract	NULL
was	NULL
run	NULL
individually	NULL
and	NULL
incubated	NULL
with	NULL
a	NULL
single	NULL
Ab	NULL
.	NULL

Immunofluorescence	NULL
microscopy	NULL
Raji	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
FCS	NULL
and	NULL
were	NULL
either	NULL
not	NULL
stimulated	NULL
(	NULL
control	NULL
cells	NULL
)	NULL
or	NULL
were	NULL
treated	NULL
with	NULL
10	NULL
nM	NULL
TPA	NULL
.	NULL

After	NULL
24	NULL
h	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
,	NULL
and	NULL
spun	NULL
down	NULL
on	NULL
microscope	NULL
slides	NULL
with	NULL
a	NULL
cytospin	NULL
(	NULL
700	NULL
rpm	NULL
,	NULL
3	NULL
min	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
fixed	NULL
with	NULL
methanol	NULL
and	NULL
incubated	NULL
with	NULL
anti-cPKC-	NULL
@	NULL
,	NULL
anti-cPKC-BII	NULL
,	NULL
or	NULL
anti-cPKC-£	NULL
Abs	NULL
for	NULL
30	NULL
min	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
before	NULL
receiving	NULL
the	NULL
fluorescein-labeled	NULL
secondary	NULL
Ab	NULL
(	NULL
F205	NULL
,	NULL
Dako	NULL
,	NULL
Glostrup	NULL
,	NULL
Denmark	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
dark	NULL
for	NULL
30	NULL
min	NULL
,	NULL
then	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
,	NULL
and	NULL
glass	NULL
covers	NULL
were	NULL
mounted	NULL
with	NULL
Fluoro-mount-G	NULL
(	NULL
Southern	NULL
Biotechnology	NULL
Associates	NULL
,	NULL
Birmingham	NULL
,	NULL
AL	NULL
)	NULL
.	NULL

An	NULL
Op-tiphot	NULL
UV	NULL
microscope	NULL
(	NULL
Nikon	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
with	NULL
a	NULL
X100	NULL
objective	NULL
was	NULL
used	NULL
for	NULL
evaluation	NULL
of	NULL
immunofluorescence	NULL
.	NULL

PKC	NULL
assay	NULL
A	NULL
specific	NULL
PKC	NULL
assay	NULL
system	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
was	NULL
used	NULL
to	NULL
measure	NULL
the	NULL
PKC	NULL
activity	NULL
in	NULL
the	NULL
subcellular	NULL
protein	NULL
fractions	NULL
prepared	NULL
from	NULL
Raji	NULL
B	NULL
cells	NULL
following	NULL
the	NULL
manufacturer	NULL
's	NULL
recommendations	NULL
.	NULL

Briefly	NULL
,	NULL
5	NULL
nmol	NULL
of	NULL
a	NULL
biotinylated	NULL
PKC	NULL
peptide	NULL
substrate	NULL
(	NULL
neurogranin	NULL
(	NULL
28-43	NULL
)	NULL
)	NULL
is	NULL
phosphorylated	NULL
by	NULL
PKCs	NULL
present	NULL
in	NULL
the	NULL
protein	NULL
fractions	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
[	NULL
y-	NULL
>	NULL
P	NULL
]	NULL
ATP	NULL
(	NULL
diluted	NULL
in	NULL
unlabeled	NULL
ATP	NULL
to	NULL
200	NULL
cpm/pmol	NULL
of	NULL
ATP	NULL
)	NULL
and	NULL
co-factors	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

Neurogranin	NULL
is	NULL
a	NULL
specific	NULL
and	NULL
potent	NULL
substrate	NULL
for	NULL
Ca**-	NULL
and	NULL
phospholipid-dependent	NULL
PKCs	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Following	NULL
phosphorylation	NULL
after	NULL
10-min	NULL
incubation	NULL
at	NULL
30°C	NULL
,	NULL
the	NULL
biotinylated	NULL
substrate	NULL
is	NULL
specifically	NULL
bound	NULL
to	NULL
streptavidin-coated	NULL
filter	NULL
discs	NULL
,	NULL
and	NULL
the	NULL
excess	NULL
free	NULL
[	NULL
y-	NULL
``	NULL
``	NULL
P	NULL
]	NULL
JATP	NULL
and	NULL
any	NULL
nonbiotinylated	NULL
proteins	NULL
phosphorylated	NULL
by	NULL
contaminating	NULL
kinases	NULL
are	NULL
washed	NULL
away	NULL
with	NULL
1	NULL
M	NULL
NaCl	NULL
.	NULL

The	NULL
radioactivity	NULL
incorporated	NULL
into	NULL
the	NULL
peptide	NULL
substrate	NULL
is	NULL
determined	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
and	NULL
reflects	NULL
the	NULL
PKC	NULL
activity	NULL
of	NULL
the	NULL
different	NULL
fractions	NULL
.	NULL

The	NULL
buffer	NULL
used	NULL
in	NULL
this	NULL
assay	NULL
(	NULL
20	NULL
mM	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
and	NULL
10	NULL
mM	NULL
MgCl	NULL
,	NULL
)	NULL
is	NULL
void	NULL
of	NULL
phospholipids	NULL
and	NULL
measures	NULL
the	NULL
active	NULL
form	NULL
of	NULL
PKC	NULL
in	NULL
the	NULL
protein	NULL
extracts	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
reactions	NULL
contained	NULL
a	NULL
PKC	NULL
coactivation	NULL
buffer	NULL
(	NULL
0.25	NULL
mM	NULL
EGTA	NULL
,	NULL
0.4	NULL
mM	NULL
CaCl	NULL
,	NULL
,	NULL
and	NULL
0.1	NULL
mg/ml	NULL
BSA	NULL
)	NULL
.	NULL

To	NULL
allow	NULL
this	NULL
assay	NULL
to	NULL
closely	NULL
reflect	NULL
the	NULL
in	NULL
vivo	NULL
situation	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
protein	NULL
extract	NULL
used	NULL
in	NULL
each	NULL
reaction	NULL
was	NULL
representative	NULL
of	NULL
a	NULL
specific	NULL
amount	NULL
of	NULL
cells	NULL
rather	NULL
than	NULL
equal	NULL
amounts	NULL
of	NULL
proteins	NULL
.	NULL

In	NULL
the	NULL
assay	NULL
,	NULL
generally	NULL
20	NULL
pug	NULL
of	NULL
soluble	NULL
proteins	NULL
and	NULL
5	NULL
ug	NULL
of	NULL
particulate	NULL
proteins	NULL
were	NULL
used	NULL
.	NULL

These	NULL
amounts	NULL
were	NULL
calculated	NULL
based	NULL
on	NULL
the	NULL
quantity	NULL
of	NULL
proteins	NULL
obtained	NULL
in	NULL
each	NULL
extraction	NULL
step	NULL
.	NULL

Moreover	NULL
,	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
was	NULL
added	NULL
to	NULL
the	NULL
soluble	NULL
fractions	NULL
to	NULL
make	NULL
them	NULL
comparable	NULL
to	NULL
the	NULL
particulate	NULL
fractions	NULL
.	NULL

Results	NULL
Specific	NULL
repression	NULL
of	NULL
AP-1-dependent	NULL
transcriptional	NULL
activation	NULL
by	NULL
a	NULL
selective	NULL
PKC	NULL
inhibitor	NULL
The	NULL
functionality	NULL
of	NULL
the	NULL
induced	NULL
PKC	NULL
activity	NULL
following	NULL
TPA	NULL
treatment	NULL
was	NULL
studied	NULL
by	NULL
transient	NULL
transfection	NULL
analyses	NULL
using	NULL
a	NULL
wild-type	NULL
DRA	NULL
promoter	NULL
construct	NULL
and	NULL
a	NULL
DRA	NULL
promoter	NULL
construct	NULL
with	NULL
point	NULL
mutations	NULL
in	NULL
the	NULL
X2	NULL
box	NULL
.	NULL

After	NULL
a	NULL
recovery	NULL
period	NULL
,	NULL
cells	NULL
were	NULL
left	NULL
untreated	NULL
or	NULL
were	NULL
stimulated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
10	NULL
nM	NULL
TPA	NULL
or	NULL
10	NULL
nM	NULL
TPA	NULL
and	NULL
GF	NULL
109203X	NULL
.	NULL

Using	NULL
the	NULL
DRA	NULL
wild-type	NULL
promoter	NULL
construct	NULL
,	NULL
10	NULL
nM	NULL
TPA	NULL
treatment	NULL
for	NULL
24	NULL
h	NULL
resulted	NULL
in	NULL
a	NULL
1.7-fold	NULL
induction	NULL
of	NULL
relative	NULL
CAT	NULL
enzymatic	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
column	NULL
2	NULL
)	NULL
compared	NULL
with	NULL
the	NULL
CAT	NULL
activity	NULL
in	NULL
nonstimulated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
<	NULL
c	NULL
2	NULL
it	NULL
(	NULL
>	NULL
3	NULL
o	NULL
9	NULL
'	NULL
_	NULL
<	NULL
O	NULL
0	NULL
-	NULL
u	NULL
.	NULL

-	NULL
LL	NULL
.	NULL

600	NULL
2	NULL
6	NULL
000	NULL
2	NULL
5	NULL
is	NULL
S3	NULL
+	NULL
a	NULL
6	NULL
+	NULL
3	NULL
-	NULL
=	NULL
3	NULL
-	NULL
3	NULL
o	NULL
c	NULL
o	NULL
5	NULL
O	NULL
<	NULL
o	NULL
O	NULL
<	NULL
o	NULL
a.	NULL
al	NULL
&	NULL
~	NULL
i-	NULL
<	NULL
<	NULL
a.	NULL
a.	NULL
i-	NULL
i	NULL
pDRASCAT	NULL
pPXM	NULL
(	NULL
-93/-91	NULL
)	NULL
FIGURE	NULL
1	NULL
.	NULL

CAT	NULL
enzymatic	NULL
activities	NULL
of	NULL
transiently	NULL
transfected	NULL
Raji	NULL
cells	NULL
.	NULL

Each	NULL
transfection	NULL
was	NULL
performed	NULL
in	NULL
triplicate	NULL
in	NULL
two	NULL
independent	NULL
experiments	NULL
and	NULL
treated	NULL
as	NULL
indicated	NULL
.	NULL

Error	NULL
bars	NULL
indicate	NULL
the	NULL
SE	NULL
.	NULL

Treatments	NULL
and	NULL
plasmids	NULL
pDRASCAT	NULL
and	NULL
pPXM	NULL
(	NULL
-93/-91	NULL
)	NULL
are	NULL
indicated	NULL
.	NULL

column	NULL
1	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
PKC	NULL
response	NULL
was	NULL
revealed	NULL
by	NULL
pretreatment	NULL
with	NULL
the	NULL
selective	NULL
PKC	NULL
inhibitor	NULL
GF	NULL
109203X	NULL
,	NULL
which	NULL
resulted	NULL
in	NULL
almost	NULL
total	NULL
abolishment	NULL
of	NULL
the	NULL
induction	NULL
obtained	NULL
by	NULL
10	NULL
nM	NULL
TPA	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
column	NULL
3	NULL
)	NULL
.	NULL

The	NULL
X2	NULL
box-specific	NULL
TPA	NULL
responsiveness	NULL
of	NULL
the	NULL
DRA	NULL
promoter	NULL
and	NULL
the	NULL
GF	NULL
109203X-specific	NULL
inhibition	NULL
were	NULL
investigated	NULL
using	NULL
pPXM	NULL
(	NULL
-93/	NULL
-91	NULL
)	NULL
as	NULL
the	NULL
target	NULL
.	NULL

This	NULL
target	NULL
plasmid	NULL
carries	NULL
clustered	NULL
point	NULL
mutations	NULL
of	NULL
the	NULL
X2	NULL
box	NULL
and	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
unresponsive	NULL
to	NULL
TPA	NULL
treatment	NULL
(	NULL
23	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
TPA	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
transcriptional	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
columns	NULL
4	NULL
and	NULL
5	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
GF	NULL
109203X	NULL
had	NULL
no	NULL
inhibitory	NULL
effect	NULL
on	NULL
the	NULL
transcriptional	NULL
activity	NULL
specified	NULL
by	NULL
this	NULL
target	NULL
plasmid	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
column	NULL
6	NULL
)	NULL
,	NULL
demonstrating	NULL
that	NULL
the	NULL
X2	NULL
box	NULL
is	NULL
the	NULL
major	NULL
target	NULL
for	NULL
PKC-mediated	NULL
TPA	NULL
activation	NULL
of	NULL
the	NULL
DRA	NULL
promoter	NULL
.	NULL

To	NULL
further	NULL
pinpoint	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
TPA	NULL
treatment	NULL
on	NULL
the	NULL
TPA	NULL
response	NULL
element	NULL
(	NULL
TRE	NULL
)	NULL
,	NULL
a	NULL
TRE-dependent	NULL
reporter	NULL
plasmid	NULL
was	NULL
used	NULL
in	NULL
an	NULL
identical	NULL
set-up	NULL
.	NULL

Raji	NULL
B	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
reporter	NULL
plasmid	NULL
pTKCAT.3XAPI	NULL
(	NULL
28	NULL
)	NULL
.	NULL

This	NULL
multimeric	NULL
AP-1	NULL
reporter	NULL
,	NULL
which	NULL
contains	NULL
three	NULL
AP-1	NULL
sites	NULL
cloned	NULL
upstream	NULL
of	NULL
a	NULL
minimal	NULL
heterologous	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
,	NULL
has	NULL
previously	NULL
been	NULL
used	NULL
to	NULL
detect	NULL
induced	NULL
CAT	NULL
enzymatic	NULL
activities	NULL
in	NULL
several	NULL
cell	NULL
types	NULL
following	NULL
TPA	NULL
treatment	NULL
(	NULL
23	NULL
,	NULL
28	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Compared	NULL
with	NULL
the	NULL
CAT	NULL
activity	NULL
in	NULL
nonstimulated	NULL
cells	NULL
,	NULL
10	NULL
nM	NULL
TPA	NULL
treatment	NULL
for	NULL
24	NULL
h	NULL
resulted	NULL
in	NULL
a	NULL
3-fold	NULL
induction	NULL
of	NULL
relative	NULL
CAT	NULL
enzymatic	NULL
activity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
PKC	NULL
response	NULL
was	NULL
revealed	NULL
by	NULL
pretreatment	NULL
with	NULL
the	NULL
selective	NULL
PKC	NULL
inhibitor	NULL
GF	NULL
109203X	NULL
%	NULL
,	NULL
which	NULL
resulted	NULL
in	NULL
almost	NULL
total	NULL
abolishment	NULL
of	NULL
the	NULL
induction	NULL
obtained	NULL
by	NULL
10	NULL
nM	NULL
TPA	NULL
treatment	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
transfections	NULL
clearly	NULL
demonstrate	NULL
and	NULL
confirm	NULL
the	NULL
PKC	NULL
dependency	NULL
of	NULL
the	NULL
TREs	NULL
,	NULL
both	NULL
in	NULL
the	NULL
complex	NULL
promoter	NULL
background	NULL
of	NULL
the	NULL
DRA	NULL
gene	NULL
promoter	NULL
and	NULL
in	NULL
a	NULL
TRE-specific	NULL
reporter	NULL
construct	NULL
.	NULL

Selective	NULL
translocations	NULL
of	NULL
PKC	NULL
isoforms	NULL
following	NULL
TPA	NULL
treatment	NULL
revealed	NULL
by	NULL
Western	NULL
blotting	NULL
To	NULL
determine	NULL
the	NULL
expression	NULL
profiles	NULL
of	NULL
PKC	NULL
isoforms	NULL
in	NULL
Raji	NULL
B	NULL
cells	NULL
,	NULL
Western	NULL
blotting	NULL
analyses	NULL
using	NULL
eight	NULL
commercially	NULL
avail	NULL
4821	NULL
able	NULL
Abs	NULL
raised	NULL
against	NULL
different	NULL
PKC	NULL
isoforms	NULL
were	NULL
performed	NULL
on	NULL
soluble	NULL
and	NULL
particulate	NULL
protein	NULL
fractions	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

The	NULL
aim	NULL
of	NULL
this	NULL
experiment	NULL
was	NULL
to	NULL
identify	NULL
which	NULL
isoforms	NULL
are	NULL
expressed	NULL
in	NULL
these	NULL
B	NULL
cells	NULL
and	NULL
,	NULL
further	NULL
,	NULL
which	NULL
isoforms	NULL
are	NULL
translocated	NULL
in	NULL
response	NULL
to	NULL
the	NULL
different	NULL
TPA	NULL
treatments	NULL
.	NULL

In	NULL
resting	NULL
cells	NULL
,	NULL
three	NULL
main	NULL
isoforms	NULL
,	NULL
cPKC-a	NULL
,	NULL
cPKC-fBII	NULL
,	NULL
and	NULL
aPKC-£	NULL
,	NULL
were	NULL
detected	NULL
in	NULL
both	NULL
the	NULL
soluble	NULL
and	NULL
the	NULL
particulate	NULL
fraction	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
lanes	NULL
1	NULL
,	NULL
2	NULL
,	NULL
8	NULL
,	NULL
9	NULL
,	NULL
10	NULL
,	NULL
and	NULL
16	NULL
)	NULL
.	NULL

The	NULL
cPKC-8	NULL
and	NULL
cPKC-e	NULL
were	NULL
both	NULL
weakly	NULL
detectable	NULL
and	NULL
exclusively	NULL
in	NULL
the	NULL
soluble	NULL
fraction	NULL
and	NULL
the	NULL
particulate	NULL
fraction	NULL
,	NULL
respectively	NULL
,	NULL
following	NULL
10	NULL
nM	NULL
TPA	NULL
treatment	NULL
for	NULL
24	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
13	NULL
)	NULL
.	NULL

The	NULL
cPKC-a	NULL
@	NULL
and	NULL
aPKC-£	NULL
were	NULL
present	NULL
as	NULL
proteins	NULL
with	NULL
apparent	NULL
molecular	NULL
masses	NULL
of	NULL
74	NULL
kDa	NULL
in	NULL
both	NULL
fractions	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
cPKC-fII	NULL
which	NULL
has	NULL
the	NULL
same	NULL
apparent	NULL
molecular	NULL
mass	NULL
as	NULL
cPKC-a	NULL
«	NULL
in	NULL
the	NULL
soluble	NULL
fraction	NULL
,	NULL
appears	NULL
as	NULL
a	NULL
doublet	NULL
in	NULL
the	NULL
particulate	NULL
fraction	NULL
,	NULL
with	NULL
apparent	NULL
molecular	NULL
masses	NULL
of	NULL
72	NULL
and	NULL
77	NULL
kDa	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
A	NULL
and	NULL
B	NULL
,	NULL
lanes	NULL
10	NULL
,	NULL
and	NULL
Fig	NULL
.	NULL

2E	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Western	NULL
blotting	NULL
of	NULL
the	NULL
fractions	NULL
prepared	NULL
from	NULL
cells	NULL
harvested	NULL
after	NULL
TPA	NULL
treatments	NULL
(	NULL
10	NULL
nM	NULL
;	NULL
10	NULL
min	NULL
,	NULL
60	NULL
min	NULL
,	NULL
and	NULL
24	NULL
h	NULL
)	NULL
was	NULL
performed	NULL
following	NULL
the	NULL
same	NULL
procedure	NULL
.	NULL

After	NULL
10	NULL
min	NULL
,	NULL
the	NULL
distributions	NULL
of	NULL
the	NULL
different	NULL
isoforms	NULL
were	NULL
unchanged	NULL
compared	NULL
with	NULL
that	NULL
in	NULL
the	NULL
control	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Detectable	NULL
differences	NULL
were	NULL
seen	NULL
after	NULL
60	NULL
min	NULL
of	NULL
TPA	NULL
treatment	NULL
:	NULL
the	NULL
amounts	NULL
of	NULL
cPKC-a	NULL
«	NULL
and	NULL
-II	NULL
decreased	NULL
in	NULL
the	NULL
soluble	NULL
fraction	NULL
,	NULL
with	NULL
a	NULL
concomitant	NULL
increase	NULL
in	NULL
the	NULL
particulate	NULL
fraction	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
cPKC-BII	NULL
band	NULL
that	NULL
increased	NULL
the	NULL
most	NULL
was	NULL
the	NULL
77-kDa	NULL
band	NULL
.	NULL

The	NULL
translocation	NULL
was	NULL
even	NULL
more	NULL
evident	NULL
after	NULL
24	NULL
h	NULL
of	NULL
TPA	NULL
treatment	NULL
in	NULL
the	NULL
soluble	NULL
fraction	NULL
,	NULL
which	NULL
was	NULL
almost	NULL
void	NULL
of	NULL
cPKC-a	NULL
@	NULL
and	NULL
cPKC-fBII	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

This	NULL
translocation	NULL
pattern	NULL
from	NULL
the	NULL
cytosol	NULL
to	NULL
the	NULL
membrane	NULL
fraction	NULL
was	NULL
also	NULL
seen	NULL
in	NULL
the	NULL
extracts	NULL
prepared	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
10	NULL
uM	NULL
TPA	NULL
for	NULL
24	NULL
h	NULL
as	NULL
well	NULL
as	NULL
in	NULL
the	NULL
extracts	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
GF	NULL
109203X	NULL
and	NULL
with	NULL
10	NULL
nM	NULL
TPA	NULL
for	NULL
24	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

After	NULL
treatment	NULL
with	NULL
10	NULL
wM	NULL
TPA	NULL
,	NULL
neither	NULL
cPKC-a	NULL
nor	NULL
cPKC-BII	NULL
was	NULL
detectable	NULL
in	NULL
the	NULL
soluble	NULL
fraction	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Further	NULL
,	NULL
only	NULL
low	NULL
amounts	NULL
of	NULL
both	NULL
these	NULL
isoforms	NULL
were	NULL
detected	NULL
in	NULL
the	NULL
particulate	NULL
fraction	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

This	NULL
difference	NULL
between	NULL
10	NULL
nM	NULL
vs	NULL
10	NULL
uM	NULL
TPA	NULL
treatment	NULL
could	NULL
reflect	NULL
the	NULL
fact	NULL
that	NULL
under	NULL
the	NULL
latter	NULL
condition	NULL
both	NULL
cPKC-a	NULL
«	NULL
and	NULL
cPKC-BII	NULL
are	NULL
down-regulated	NULL
.	NULL

The	NULL
atypical	NULL
aPKC-¢	NULL
was	NULL
not	NULL
translocated	NULL
following	NULL
10	NULL
nM	NULL
TPA	NULL
treatment	NULL
for	NULL
24	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lanes	NULL
8	NULL
vs	NULL
16	NULL
)	NULL
.	NULL

However	NULL
,	NULL
proteolytic	NULL
degradation	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
particulate	NULL
fraction	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lane	NULL
16	NULL
)	NULL
.	NULL

Such	NULL
proteolytic	NULL
degradation	NULL
was	NULL
not	NULL
seen	NULL
after	NULL
1	NULL
h	NULL
of	NULL
TPA	NULL
treatment	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
relative	NULL
molecular	NULL
masses	NULL
of	NULL
the	NULL
two	NULL
cPKC-BII	NULL
isoforms	NULL
found	NULL
in	NULL
the	NULL
particulate	NULL
fractions	NULL
,	NULL
a	NULL
7.5	NULL
%	NULL
SDS-PAGE	NULL
was	NULL
run	NULL
with	NULL
an	NULL
adequate	NULL
protein	NULL
size	NULL
marker	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

The	NULL
two	NULL
bands	NULL
were	NULL
identified	NULL
to	NULL
be	NULL
distinct	NULL
cPKC-BII	NULL
isoforms	NULL
with	NULL
relative	NULL
molecular	NULL
masses	NULL
of	NULL
72	NULL
and	NULL
77	NULL
kDa	NULL
,	NULL
respectively	NULL
.	NULL

Following	NULL
10	NULL
nM	NULL
TPA	NULL
treatment	NULL
,	NULL
the	NULL
amounts	NULL
of	NULL
both	NULL
72-and	NULL
77-kDa	NULL
forms	NULL
were	NULL
increased	NULL
in	NULL
the	NULL
particulate	NULL
fractions	NULL
(	NULL
Fig	NULL
.	NULL

2E	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
after	NULL
treatment	NULL
with	NULL
10	NULL
M	NULL
TPA	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
the	NULL
72-kDa	NULL
form	NULL
decreased	NULL
,	NULL
with	NULL
a	NULL
concomitant	NULL
increase	NULL
in	NULL
the	NULL
77-kDa	NULL
form	NULL
(	NULL
Fig	NULL
.	NULL

26	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
both	NULL
cPKC-a	NULL
and	NULL
cPKC-BII	NULL
are	NULL
translocated	NULL
in	NULL
response	NULL
to	NULL
TPA	NULL
treatment	NULL
,	NULL
and	NULL
that	NULL
following	NULL
translocation	NULL
,	NULL
cPKC-fBII	NULL
is	NULL
subjected	NULL
to	NULL
structural	NULL
modification	NULL
.	NULL

Translocation	NULL
of	NULL
cPKC-a	NULL
and	NULL
cPKC-BII	NULL
to	NULL
the	NULL
perinuclear	NULL
region	NULL
in	NULL
response	NULL
to	NULL
phorbol	NULL
ester	NULL
administration	NULL
Immunofluorescence	NULL
was	NULL
performed	NULL
on	NULL
Raji	NULL
B	NULL
cells	NULL
using	NULL
antisera	NULL
specific	NULL
for	NULL
the	NULL
highly	NULL
expressed	NULL
cPKC-a	NULL
@	NULL
and	NULL
cPKC-BII	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

In	NULL
resting	NULL
cells	NULL
,	NULL
cPKC-a	NULL
«	NULL
and	NULL
cPKC-BII	NULL
were	NULL
equally	NULL
distributed	NULL
between	NULL
the	NULL
cytosol	NULL
and	NULL
the	NULL
membranes	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Following	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
for	NULL
24	NULL
h	NULL
with	NULL
10	NULL
nM	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
4822	NULL
ROLE	NULL
OF	NULL
PKC	NULL
IN	NULL
ACTIVATED	NULL
DRA	NULL
TRANSCRIPTION	NULL
a	NULL
II	NULL
«	NULL
BH	NULL
o	NULL
II	NULL
a	NULL
«	NULL
BH	NULL
3	NULL
y	NULL
e	NULL
n	NULL
0	NULL
t	NULL
a	NULL
BH	NULL
&	NULL
y	NULL
e	NULL
n	NULL
0	NULL
¢	NULL
C	NULL
B	NULL
B	NULL
D	NULL
B	NULL
BH	NULL
[	NULL
1_z	NULL
3	NULL
4	NULL
5s	NULL
6	NULL
7	NULL
8	NULL
]	NULL
(	NULL
a	NULL
10	NULL
n	NULL
iz	NULL
ii	NULL
14	NULL
is	NULL
ie	NULL
)	NULL
*	NULL
kDa	NULL
kDa	NULL
kDa	NULL
97	NULL
=-	NULL
97	NULL
=-97	NULL
-	NULL
97-	NULL
«	NULL
@	NULL
4	NULL
wan	NULL
«	NULL
aa	NULL
t=	NULL
ae	NULL
|	NULL
=	NULL
gg	NULL
-	NULL
land	NULL
63	NULL
69	NULL
-	NULL
69	NULL
SOLUBLE	NULL
PARTICULATE	NULL
S	NULL
P	NULL
S	NULL
P	NULL
E	NULL
Control	NULL
TPA	NULL
_	NULL
TPA	NULL
B	NULL
10	NULL
nM	NULL
-	NULL
10	NULL
pM	NULL
a	NULL
Bil	NULL
&	NULL
y	NULL
e	NULL
n	NULL
0	NULL
C	NULL
a	NULL
Bl	NULL
8	NULL
y	NULL
e	NULL
n	NULL
6	NULL
to	NULL
_	NULL
spa	NULL
[	NULL
1-23	NULL
]	NULL
[	NULL
1	NULL
2	NULL
3	NULL
O4	NULL
O5	NULL
6	NULL
7	NULL
s	NULL
]	NULL
[	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
]	NULL
94	NULL
kDa	NULL
kDa	NULL
97	NULL
-	NULL
97	NULL
«	NULL
ame	NULL
«	NULL
»	NULL
$	NULL
%	NULL
«	NULL
atin	NULL
69	NULL
-	NULL
]	NULL
69	NULL
-	NULL
77	NULL
-	NULL
w	NULL
-	NULL
MG	NULL
|	NULL
«	NULL
te	NULL
72	NULL
-	NULL
|	NULL
won	NULL
-	NULL
d	NULL
#	NULL
SOLUBLE	NULL
PARTICULATE	NULL
e	NULL
FIGURE	NULL
2	NULL
.	NULL

-	NULL
Western	NULL
blotting	NULL
analyses	NULL
on	NULL
protein	NULL
extracts	NULL
with	NULL
specific	NULL
antisera	NULL
against	NULL
different	NULL
PKC	NULL
isoforms	NULL
(	NULL
as	NULL
indicated	NULL
)	NULL
.	NULL

A	NULL
,	NULL
Soluble	NULL
and	NULL
particulate	NULL
fractions	NULL
from	NULL
resting	NULL
cells	NULL
;	NULL
B	NULL
,	NULL
soluble	NULL
and	NULL
particulate	NULL
fractions	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
TPA	NULL
(	NULL
10	NULL
nM	NULL
,	NULL
24	NULL
h	NULL
)	NULL
;	NULL
C	NULL
,	NULL
cPKC-a	NULL
and	NULL
cPKC-BII	NULL
in	NULL
soluble	NULL
(	NULL
S	NULL
)	NULL
and	NULL
particulate	NULL
(	NULL
P	NULL
)	NULL
fractions	NULL
from	NULL
TPA-induced	NULL
cells	NULL
(	NULL
10	NULL
uM	NULL
,	NULL
24	NULL
h	NULL
)	NULL
;	NULL
D	NULL
,	NULL
cPKC-a	NULL
and	NULL
in	NULL
soluble	NULL
(	NULL
S	NULL
)	NULL
and	NULL
particulate	NULL
(	NULL
P	NULL
)	NULL
fractions	NULL
from	NULL
TPA-induced	NULL
cells	NULL
(	NULL
10	NULL
nM	NULL
,	NULL
24	NULL
h	NULL
)	NULL
pretreated	NULL
with	NULL
2	NULL
uM	NULL
GF	NULL
203109X	NULL
%	NULL
;	NULL
£	NULL
,	NULL
cPKC-BII	NULL
in	NULL
particulate	NULL
fractions	NULL
from	NULL
resting	NULL
cells	NULL
(	NULL
Zane	NULL
7	NULL
)	NULL
and	NULL
cells	NULL
treated	NULL
with	NULL
either	NULL
10	NULL
nM	NULL
TPA	NULL
for	NULL
24	NULL
h	NULL
(	NULL
Zane	NULL
2	NULL
)	NULL
or	NULL
10	NULL
wM	NULL
TPA	NULL
for	NULL
24	NULL
h	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
on	NULL
7.5	NULL
%	NULL
SDS-PAGE	NULL
.	NULL

The	NULL
extracts	NULL
were	NULL
run	NULL
on	NULL
the	NULL
same	NULL
gel	NULL
.	NULL

The	NULL
lanes	NULL
shown	NULL
are	NULL
cut	NULL
from	NULL
one	NULL
picture	NULL
.	NULL

TPA	NULL
,	NULL
the	NULL
cytosol	NULL
was	NULL
depleted	NULL
of	NULL
both	NULL
these	NULL
PKC	NULL
isoforms	NULL
,	NULL
with	NULL
a	NULL
parallel	NULL
increase	NULL
in	NULL
staining	NULL
of	NULL
the	NULL
perinuclear	NULL
membrane	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

Induced	NULL
in	NULL
vitro	NULL
PKC	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
TPA	NULL
treatment	NULL
To	NULL
investigate	NULL
possible	NULL
changes	NULL
in	NULL
bonafide	NULL
PKC	NULL
activities	NULL
in	NULL
response	NULL
to	NULL
TPA	NULL
treatment	NULL
,	NULL
the	NULL
protein	NULL
extracts	NULL
previously	NULL
used	NULL
in	NULL
Western	NULL
analyses	NULL
(	NULL
see	NULL
above	NULL
)	NULL
were	NULL
analyzed	NULL
with	NULL
a	NULL
selective	NULL
PKC	NULL
assay	NULL
.	NULL

This	NULL
assay	NULL
takes	NULL
advantage	NULL
of	NULL
the	NULL
PKC-specific	NULL
in	NULL
vitro	NULL
phosphorylation	NULL
of	NULL
a	NULL
neurogranin	NULL
peptide	NULL
corresponding	NULL
to	NULL
amino	NULL
acids	NULL
28	NULL
to	NULL
43	NULL
.	NULL

This	NULL
peptide	NULL
serves	NULL
as	NULL
a	NULL
specific	NULL
substrate	NULL
for	NULL
cal-cium-	NULL
and	NULL
phospholipid-dependent	NULL
cPKC	NULL
and	NULL
calcium-indepen-dent	NULL
nPKC	NULL
isozymes	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
this	NULL
assay	NULL
allows	NULL
discrimination	NULL
between	NULL
activatable	NULL
and	NULL
active	NULL
PKC	NULL
by	NULL
the	NULL
presence	NULL
or	NULL
the	NULL
absence	NULL
of	NULL
phospholipids	NULL
in	NULL
the	NULL
reaction	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
assay	NULL
was	NULL
performed	NULL
both	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
phospholipids	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
with	NULL
a	NULL
buffer	NULL
void	NULL
of	NULL
phospholipids	NULL
to	NULL
measure	NULL
the	NULL
active	NULL
forms	NULL
of	NULL
PKC	NULL
.	NULL

The	NULL
soluble	NULL
fraction	NULL
displayed	NULL
a	NULL
marked	NULL
decrease	NULL
in	NULL
PKC	NULL
activity	NULL
following	NULL
TPA	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
columns	NULL
1-4	NULL
)	NULL
paralleled	NULL
by	NULL
an	NULL
increase	NULL
in	NULL
PKC	NULL
activity	NULL
in	NULL
the	NULL
particulate	NULL
fraction	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
columns	NULL
6-9	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
GF	NULL
109203X	NULL
inhibited	NULL
all	NULL
PKC	NULL
activity	NULL
in	NULL
the	NULL
particulate	NULL
fraction	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
compare	NULL
columns	NULL
9	NULL
and	NULL
10	NULL
)	NULL
,	NULL
whereas	NULL
GF	NULL
109203X	NULL
did	NULL
not	NULL
influence	NULL
the	NULL
residual	NULL
PKC	NULL
activity	NULL
in	NULL
the	NULL
soluble	NULL
fraction	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
column	NULL
5	NULL
)	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
the	NULL
enzymatic	NULL
activity	NULL
of	NULL
phospholipid-dependent	NULL
PKC	NULL
isoforms	NULL
was	NULL
increased	NULL
in	NULL
the	NULL
particulate	NULL
fractions	NULL
in	NULL
response	NULL
to	NULL
TPA	NULL
treatment	NULL
,	NULL
with	NULL
a	NULL
concomitant	NULL
decrease	NULL
in	NULL
PKC	NULL
activities	NULL
in	NULL
the	NULL
soluble	NULL
fractions	NULL
.	NULL

Discussion	NULL
GF	NULL
109203X	NULL
almost	NULL
completely	NULL
abrogated	NULL
the	NULL
TPA-induced	NULL
CAT	NULL
activity	NULL
of	NULL
the	NULL
wild-type	NULL
DRA	NULL
promoter	NULL
target	NULL
plasmid	NULL
and	NULL
the	NULL
AP-1-dependent	NULL
target	NULL
plasmid	NULL
in	NULL
response	NULL
to	NULL
10	NULL
nM	NULL
TPA	NULL
treatment	NULL
.	NULL

Thus	NULL
,	NULL
GF	NULL
109203X	NULL
efficiently	NULL
inhibits	NULL
TPA-mediated	NULL
PKC	NULL
activity	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

The	NULL
bisindolylmaleimide	NULL
GF	NULL
109203X	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
a	NULL
selective	NULL
and	NULL
potent	NULL
inhibitor	NULL
of	NULL
PKC	NULL
both	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
by	NULL
interacting	NULL
with	NULL
the	NULL
catalytic	NULL
domain	NULL
and	NULL
by	NULL
competing	NULL
for	NULL
ATP	NULL
binding	NULL
(	NULL
34-36	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
the	NULL
expression	NULL
patterns	NULL
of	NULL
PKC	NULL
isoforms	NULL
and	NULL
the	NULL
functional	NULL
aspects	NULL
of	NULL
PKC-mediated	NULL
signaling	NULL
were	NULL
determined	NULL
in	NULL
human	NULL
Raji	NULL
B	NULL
cells	NULL
.	NULL

The	NULL
Ca*	NULL
*	NULL
-dependent	NULL
cPKC-a	NULL
and	NULL
-BII	NULL
as	NULL
well	NULL
as	NULL
the	NULL
atypical	NULL
,	NULL
Ca**-independent	NULL
could	NULL
easily	NULL
be	NULL
detected	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
whereas	NULL
nPKC-8	NULL
and	NULL
nPKC-e	NULL
displayed	NULL
weaker	NULL
signals	NULL
.	NULL

This	NULL
expression	NULL
pattern	NULL
is	NULL
largely	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
previously	NULL
reported	NULL
expression	NULL
of	NULL
PKC	NULL
isoforms	NULL
in	NULL
other	NULL
human	NULL
B	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
in	NULL
murine	NULL
pre-B	NULL
and	NULL
B	NULL
cells	NULL
(	NULL
37-39	NULL
)	NULL
.	NULL

The	NULL
use	NULL
of	NULL
soluble	NULL
and	NULL
particulate	NULL
protein	NULL
fractions	NULL
prepared	NULL
from	NULL
resting	NULL
cells	NULL
and	NULL
cells	NULL
treated	NULL
either	NULL
with	NULL
10	NULL
nM	NULL
TPA	NULL
or	NULL
10	NULL
JM	NULL
TPA	NULL
in	NULL
Western	NULL
blotting	NULL
analyses	NULL
revealed	NULL
that	NULL
both	NULL
cPKC-	NULL
«	NULL
and	NULL
-BII	NULL
were	NULL
translocated	NULL
to	NULL
the	NULL
particulate	NULL
fraction	NULL
.	NULL

Treatment	NULL
with	NULL
10	NULL
uM	NULL
TPA	NULL
for	NULL
24	NULL
h	NULL
led	NULL
to	NULL
a	NULL
complete	NULL
translocation	NULL
from	NULL
the	NULL
soluble	NULL
to	NULL
the	NULL
particulate	NULL
fraction	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
,	NULL
which	NULL
was	NULL
confirmed	NULL
by	NULL
immunofluorescence	NULL
analyses	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
subcellular	NULL
localization	NULL
of	NULL
aPKC-£	NULL
,	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
findings	NULL
of	NULL
other	NULL
studies	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

15	NULL
)	NULL
,	NULL
remained	NULL
unaffected	NULL
by	NULL
phorbol	NULL
ester	NULL
treatment	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
FIGURE	NULL
3	NULL
.	NULL

Immunofluorescence	NULL
microscopy	NULL
on	NULL
Raji	NULL
B	NULL
cells	NULL
treated	NULL
with	NULL
an	NULL
anti-cPKC-a	NULL
Ab	NULL
in	NULL
resting	NULL
cells	NULL
(	NULL
4	NULL
)	NULL
and	NULL
cells	NULL
treated	NULL
with	NULL
10	NULL
nM	NULL
TPA	NULL
for	NULL
24	NULL
h	NULL
(	NULL
B	NULL
)	NULL
and	NULL
treated	NULL
with	NULL
an	NULL
anti-cPKC-BII	NULL
Ab	NULL
in	NULL
resting	NULL
cells	NULL
(	NULL
C	NULL
)	NULL
and	NULL
cells	NULL
treated	NULL
with	NULL
10	NULL
nM	NULL
TPA	NULL
for	NULL
24	NULL
h	NULL
(	NULL
D	NULL
)	NULL
.	NULL

4823	NULL
14	NULL
unit	NULL
)	NULL
12	NULL
PKC-activity	NULL
{	NULL
arbitrary	NULL
10	NULL
control	NULL
control	NULL
TPA	NULL
10nM	NULL
2h	NULL
TPA	NULL
10nM	NULL
4h	NULL
TPA	NULL
10nM	NULL
24h	NULL
TPA	NULL
10nM	NULL
24h+GF	NULL
TPA	NULL
10nM	NULL
2h	NULL
TPA	NULL
10nM	NULL
4h	NULL
TPA	NULL
10nM	NULL
24h	NULL
TPA	NULL
10nM	NULL
24h+GF	NULL
Soluble	NULL
Particulate	NULL
FIGURE	NULL
4	NULL
.	NULL

Activated	NULL
(	NULL
reaction	NULL
without	NULL
phospholipids	NULL
)	NULL
in	NULL
vitro	NULL
PKC	NULL
activities	NULL
(	NULL
relative	NULL
units	NULL
;	NULL
lane	NULL
I	NULL
(	NULL
control	NULL
)	NULL
is	NULL
set	NULL
at	NULL
10	NULL
)	NULL
from	NULL
five	NULL
different	NULL
protein	NULL
extracts	NULL
from	NULL
soluble	NULL
and	NULL
particulate	NULL
fractions	NULL
,	NULL
respectively	NULL
,	NULL
are	NULL
shown	NULL
(	NULL
control	NULL
=	NULL
untreated	NULL
Raji	NULL
cells	NULL
;	NULL
stimulations	NULL
are	NULL
indicated	NULL
)	NULL
.	NULL

Error	NULL
bars	NULL
indicate	NULL
the	NULL
SE	NULL
obtained	NULL
from	NULL
two	NULL
experiments	NULL
.	NULL

When	NULL
soluble	NULL
and	NULL
particulate	NULL
fractions	NULL
prepared	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
10	NULL
nM	NULL
TPA	NULL
for	NULL
24	NULL
h	NULL
were	NULL
compared	NULL
,	NULL
PKC-BII	NULL
appeared	NULL
as	NULL
a	NULL
72-/77-kDa	NULL
doublet	NULL
in	NULL
the	NULL
particulate	NULL
fraction	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
B	NULL
and	NULL
E	NULL
)	NULL
.	NULL

Two	NULL
distinct	NULL
cPKC-II	NULL
bands	NULL
have	NULL
been	NULL
reported	NULL
previously	NULL
in	NULL
the	NULL
B	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
IM-9	NULL
and	NULL
BJA-B	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Most	NULL
likely	NULL
,	NULL
this	NULL
size	NULL
difference	NULL
reflects	NULL
a	NULL
posttranslational	NULL
modification	NULL
in	NULL
response	NULL
to	NULL
activation	NULL
.	NULL

The	NULL
larger	NULL
(	NULL
77-kDa	NULL
)	NULL
band	NULL
was	NULL
reported	NULL
to	NULL
resist	NULL
down-regulation	NULL
by	NULL
long	NULL
term	NULL
phorbol	NULL
ester	NULL
treatment	NULL
(	NULL
40	NULL
)	NULL
.	NULL

This	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
our	NULL
finding	NULL
,	NULL
which	NULL
shows	NULL
a	NULL
sustained	NULL
amount	NULL
of	NULL
the	NULL
77-kDa	NULL
band	NULL
of	NULL
cPKC-BII	NULL
in	NULL
the	NULL
particulate	NULL
fraction	NULL
after	NULL
both	NULL
long	NULL
term	NULL
and	NULL
high	NULL
dose	NULL
TPA	NULL
treatment	NULL
.	NULL

Under	NULL
these	NULL
conditions	NULL
,	NULL
the	NULL
72-kDa	NULL
cPKC-BII	NULL
band	NULL
was	NULL
almost	NULL
undetectable	NULL
.	NULL

Moreover	NULL
,	NULL
these	NULL
two	NULL
cPKC-BII	NULL
forms	NULL
were	NULL
never	NULL
detected	NULL
in	NULL
soluble	NULL
fractions	NULL
of	NULL
either	NULL
resting	NULL
or	NULL
TPA-treated	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
translocation	NULL
induced	NULL
by	NULL
TPA	NULL
also	NULL
involves	NULL
a	NULL
structural	NULL
modification	NULL
of	NULL
cPKC-BII	NULL
resulting	NULL
in	NULL
the	NULL
doublet	NULL
.	NULL

Additionally	NULL
,	NULL
treatment	NULL
with	NULL
the	NULL
selective	NULL
PKC	NULL
inhibitor	NULL
GF	NULL
109203X	NULL
was	NULL
performed	NULL
before	NULL
treatment	NULL
with	NULL
10	NULL
nM	NULL
TPA	NULL
.	NULL

This	NULL
treatment	NULL
did	NULL
not	NULL
influence	NULL
translocation	NULL
of	NULL
the	NULL
PKC	NULL
isoforms	NULL
in	NULL
response	NULL
to	NULL
TPA	NULL
treatment	NULL
.	NULL

However	NULL
,	NULL
selective	NULL
PKC	NULL
inhibition	NULL
was	NULL
revealed	NULL
by	NULL
two	NULL
criteria	NULL
.	NULL

Firstly	NULL
,	NULL
in	NULL
the	NULL
PKC	NULL
assay	NULL
,	NULL
complete	NULL
inhibition	NULL
of	NULL
the	NULL
induction	NULL
mediated	NULL
by	NULL
10	NULL
nM	NULL
TPA	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
particulate	NULL
fraction	NULL
when	NULL
the	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
GF	NULL
109203X	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
actual	NULL
translocation	NULL
event	NULL
appears	NULL
to	NULL
be	NULL
independent	NULL
of	NULL
binding	NULL
of	NULL
ATP	NULL
to	NULL
the	NULL
PKC	NULL
enzymes	NULL
.	NULL

At	NULL
the	NULL
concentration	NULL
of	NULL
2	NULL
M	NULL
used	NULL
in	NULL
the	NULL
present	NULL
investigation	NULL
,	NULL
GF	NULL
109203X	NULL
is	NULL
expected	NULL
to	NULL
inhibit	NULL
all	NULL
PKC	NULL
isoforms	NULL
expressed	NULL
in	NULL
these	NULL
B	NULL
cells	NULL
with	NULL
a	NULL
ranked	NULL
order	NULL
of	NULL
potency	NULL
(	NULL
classical	NULL
>	NULL
novel	NULL
>	NULL
atypical	NULL
)	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Also	NULL
,	NULL
the	NULL
binding	NULL
of	NULL
GF	NULL
109203X	NULL
is	NULL
regulated	NULL
by	NULL
a	NULL
binding	NULL
constant	NULL
of	NULL
K	NULL
,	NULL
=	NULL
10	NULL
nM	NULL
,	NULL
and	NULL
during	NULL
the	NULL
preparation	NULL
of	NULL
the	NULL
extracts	NULL
,	NULL
some	NULL
of	NULL
the	NULL
inhibitory	NULL
effect	NULL
might	NULL
be	NULL
lost	NULL
,	NULL
explaining	NULL
the	NULL
basal	NULL
PKC	NULL
activities	NULL
in	NULL
the	NULL
in	NULL
vitro	NULL
PKC	NULL
assay	NULL
.	NULL

The	NULL
PKC	NULL
isoforms	NULL
involved	NULL
in	NULL
activation	NULL
of	NULL
AP-1	NULL
in	NULL
Raji	NULL
B	NULL
cells	NULL
remain	NULL
to	NULL
be	NULL
deter-mined	NULL
.	NULL

Further	NULL
analyses	NULL
using	NULL
immunodepletion	NULL
and	NULL
isoform-spe-cific	NULL
inhibition	NULL
by	NULL
expression	NULL
of	NULL
dominant	NULL
negative	NULL
PKCs	NULL
should	NULL
resolve	NULL
this	NULL
question	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
4824	NULL
Raji	NULL
B	NULL
cells	NULL
have	NULL
rapid	NULL
phosphoinositol	NULL
breakdown	NULL
and	NULL
PKC	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
B	NULL
cell	NULL
Ag-induced	NULL
signal	NULL
transduction	NULL
and	NULL
should	NULL
represent	NULL
an	NULL
appropriate	NULL
model	NULL
for	NULL
B	NULL
lymphocyte	NULL
signaling	NULL
.	NULL

However	NULL
,	NULL
the	NULL
basal	NULL
PKC	NULL
activities	NULL
seen	NULL
in	NULL
resting	NULL
cells	NULL
suggest	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
EBV	NULL
proteins	NULL
that	NULL
leads	NULL
to	NULL
the	NULL
transformation	NULL
of	NULL
B	NULL
cells	NULL
has	NULL
preactivated	NULL
PKC	NULL
signaling	NULL
to	NULL
some	NULL
extent	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
TPA-activated	NULL
expression	NULL
of	NULL
the	NULL
HLA-DRA	NULL
gene	NULL
was	NULL
investigated	NULL
in	NULL
Raji	NULL
B	NULL
cells	NULL
.	NULL

AP-1	NULL
heterodimers	NULL
containing	NULL
c-Fos	NULL
were	NULL
shown	NULL
to	NULL
be	NULL
essential	NULL
for	NULL
activated	NULL
transcription	NULL
of	NULL
the	NULL
HLA-DRA	NULL
gene	NULL
in	NULL
response	NULL
to	NULL
PKC	NULL
signaling	NULL
(	NULL
23	NULL
)	NULL
.	NULL

PKC-dependent	NULL
up-regulation	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
of	NULL
macrophages	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
activation	NULL
of	NULL
PKC	NULL
appears	NULL
to	NULL
be	NULL
a	NULL
crucial	NULL
mechanism	NULL
for	NULL
efficient	NULL
Ag	NULL
presentation	NULL
by	NULL
modulation	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
gene	NULL
expression	NULL
in	NULL
both	NULL
macrophages	NULL
and	NULL
B	NULL
cells	NULL
(	NULL
42	NULL
,	NULL
43	NULL
)	NULL
.	NULL

The	NULL
exact	NULL
contribution	NULL
of	NULL
selective	NULL
PKC	NULL
isoforms	NULL
to	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
in	NULL
these	NULL
cells	NULL
remains	NULL
to	NULL
be	NULL
investigated	NULL
.	NULL

However	NULL
,	NULL
it	NULL
was	NULL
recently	NULL
reported	NULL
that	NULL
targeted	NULL
disruption	NULL
of	NULL
the	NULL
murine	NULL
gene	NULL
encoding	NULL
cPKC-BI	NULL
and	NULL
cPKC-fII	NULL
resulted	NULL
in	NULL
immunodeficiency	NULL
with	NULL
impaired	NULL
humoral	NULL
immune	NULL
responses	NULL
,	NULL
implicating	NULL
a	NULL
crucial	NULL
role	NULL
for	NULL
this	NULL
PKC	NULL
isoenzyme	NULL
in	NULL
immunity	NULL
(	NULL
44	NULL
)	NULL
.	NULL

The	NULL
data	NULL
from	NULL
our	NULL
study	NULL
are	NULL
in	NULL
accordance	NULL
with	NULL
these	NULL
findings	NULL
,	NULL
suggesting	NULL
that	NULL
cPKC-BII	NULL
may	NULL
be	NULL
a	NULL
key	NULL
component	NULL
in	NULL
the	NULL
PKC-dependent	NULL
triggering	NULL
of	NULL
a	NULL
functional	NULL
immune	NULL
response	NULL
,	NULL
including	NULL
potentiated	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
Ags	NULL
.	NULL

The	NULL
functional	NULL
implication	NULL
of	NULL
the	NULL
structural	NULL
modification	NULL
of	NULL
cPKC-BII	NULL
remains	NULL
to	NULL
be	NULL
investigated	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Drs	NULL
.	NULL

E.	NULL
Nénberg	NULL
and	NULL
S.	NULL
Pihlman	NULL
for	NULL
valuable	NULL
comments	NULL
,	NULL
Dr.	NULL
B.	NULL
M.	NULL
Peterlin	NULL
for	NULL
providing	NULL
the	NULL
pDRASCAT	NULL
and	NULL
pPXM	NULL
plasmids	NULL
,	NULL
and	NULL
Dr.	NULL
S.	NULL
Bohm	NULL
for	NULL
providing	NULL
the	NULL
pTKCAT.3XAP-1	NULL
plasmid	NULL
.	NULL

References	NULL
1	NULL
.	NULL

DeFranco	NULL
,	NULL
A.	NULL
L.	NULL
1992	NULL
.	NULL

Tyrosine	NULL
phosphorylation	NULL
and	NULL
the	NULL
mechanism	NULL
of	NULL
signal	NULL
transduction	NULL
by	NULL
the	NULL
B-lymphocyte	NULL
antigen	NULL
receptor	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

210:381	NULL
.	NULL

2	NULL
.	NULL

Nishizuka	NULL
,	NULL
Y	NULL
.	NULL

1992	NULL
.	NULL

Intracellular	NULL
signaling	NULL
by	NULL
hydrolysis	NULL
of	NULL
phospholipids	NULL
and	NULL
activation	NULL
of	NULL
PKC	NULL
.	NULL

Science	NULL
258:607	NULL
.	NULL

3	NULL
.	NULL

Law	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
M.	NULL
R.	NULL
Gold	NULL
,	NULL
and	NULL
A.	NULL
L.	NULL
DeFranco	NULL
.	NULL

1992	NULL
.	NULL

Examination	NULL
of	NULL
B	NULL
lymphoid	NULL
cell	NULL
lines	NULL
for	NULL
membrane	NULL
immunoglobulin-stimulated	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
src-family	NULL
tyrosine	NULL
kinase	NULL
mRNA	NULL
expression	NULL
.	NULL

Mol	NULL
.	NULL

Immunol	NULL
.	NULL

29:917	NULL
.	NULL

4	NULL
.	NULL

Nakamura	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Y.	NULL
Nishizuka	NULL
.	NULL

1994	NULL
.	NULL

Lipid	NULL
mediators	NULL
and	NULL
protein	NULL
kinase	NULL
C	NULL
activation	NULL
for	NULL
the	NULL
intracellular	NULL
signaling	NULL
network	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

115:1029	NULL
.	NULL

5	NULL
.	NULL

Divecha	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
R.	NULL
F.	NULL
Irvine	NULL
.	NULL

1995	NULL
.	NULL

Phospholipid	NULL
signaling	NULL
.	NULL

Cell	NULL
80:269	NULL
.	NULL

6	NULL
.	NULL

Chiles	NULL
,	NULL
T.	NULL
C.	NULL
,	NULL
and	NULL
T.	NULL
L.	NULL
Rothstein	NULL
.	NULL

1992	NULL
.	NULL

Surface	NULL
Ig	NULL
receptor-induced	NULL
nuclear	NULL
AP-1-dependent	NULL
expression	NULL
in	NULL
B-lymphocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

149:825	NULL
.	NULL

7	NULL
.	NULL

Huo	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
T.	NULL
L.	NULL
Rothstein	NULL
.	NULL

1995	NULL
.	NULL

Receptor-specific	NULL
induction	NULL
of	NULL
individual	NULL
AP-1	NULL
components	NULL
in	NULL
B	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:3300	NULL
.	NULL

8	NULL
.	NULL

Burns	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Bell	NULL
.	NULL

1991	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
contains	NULL
two	NULL
phorbol	NULL
ester	NULL
binding	NULL
domains	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266:18330	NULL
.	NULL

9	NULL
.	NULL

Takai	NULL
,	NULL
Y.	NULL
,	NULL
A.	NULL
Kishimoto	NULL
,	NULL
Y.	NULL
Iwasa	NULL
,	NULL
Y.	NULL
Kawahara	NULL
,	NULL
T.	NULL
Mori	NULL
,	NULL
and	NULL
Y.	NULL
Nishizuka	NULL
.	NULL

1979	NULL
.	NULL

Calcium-dependent	NULL
activation	NULL
of	NULL
a	NULL
multifunctional	NULL
protein	NULL
kinase	NULL
by	NULL
membrane	NULL
phospholipids	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

254:3692	NULL
.	NULL

10	NULL
.	NULL

Castagna	NULL
,	NULL
M.	NULL
,	NULL
Y.	NULL
Takai	NULL
,	NULL
K.	NULL
Kaibuchi	NULL
,	NULL
K.	NULL
Sano	NULL
,	NULL
U.	NULL
Kikkawa	NULL
,	NULL
and	NULL
Y.	NULL
Nishizuka	NULL
.	NULL

1982	NULL
.	NULL

Direct	NULL
activation	NULL
of	NULL
calcium-activated	NULL
,	NULL
phospholipid-dependent	NULL
protein	NULL
kinase	NULL
by	NULL
turnor-promoting	NULL
phorbol	NULL
esters	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

257:7847	NULL
.	NULL

11	NULL
.	NULL

Huang	NULL
,	NULL
C.	NULL
,	NULL
P.	NULL
C.	NULL
Schmid	NULL
,	NULL
W.-Y	NULL
.	NULL

Ma	NULL
,	NULL
H.	NULL
H.	NULL
O.	NULL
Schmid	NULL
,	NULL
and	NULL
Z.	NULL
Dong	NULL
.	NULL

1997	NULL
.	NULL

Phosphatidylinositol-3	NULL
kinase	NULL
is	NULL
necessary	NULL
for	NULL
12-O-tetradecanoylphorbol-13-acetate-induced	NULL
cell	NULL
transformation	NULL
and	NULL
activated	NULL
protein	NULL
1	NULL
activation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:4187	NULL
.	NULL

12	NULL
.	NULL

Gschwendt	NULL
,	NULL
M.	NULL
,	NULL
W.	NULL
Kittstein	NULL
,	NULL
and	NULL
F.	NULL
Marks	NULL
.	NULL

1991	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
activation	NULL
by	NULL
phorbol	NULL
esters	NULL
:	NULL
do	NULL
cysteine-rich	NULL
regions	NULL
and	NULL
pseudosubstrate	NULL
motifs	NULL
play	NULL
a	NULL
role	NULL
?	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

16:167	NULL
.	NULL

13	NULL
.	NULL

Hug	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
T.	NULL
F.	NULL
Sarre	NULL
.	NULL

1993	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
isoenzymes	NULL
:	NULL
divergence	NULL
in	NULL
signal	NULL
transduction	NULL
?	NULL

Biochem	NULL
.	NULL

J	NULL
.	NULL

291:329	NULL
.	NULL

14	NULL
.	NULL

Dekker	NULL
,	NULL
L.	NULL
V.	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Parker	NULL
.	NULL

1994	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
:	NULL
a	NULL
question	NULL
of	NULL
specificity	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

19:73	NULL
.	NULL

15	NULL
.	NULL

Buchner	NULL
,	NULL
K.	NULL
1995	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
in	NULL
the	NULL
transduction	NULL
of	NULL
signals	NULL
toward	NULL
and	NULL
within	NULL
the	NULL
cell	NULL
nucleus	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

228:211	NULL
.	NULL

16	NULL
.	NULL

Blumberg	NULL
,	NULL
P.-M.	NULL
1991	NULL
.	NULL

Complexities	NULL
of	NULL
the	NULL
protein	NULL
kinase	NULL
C	NULL
pathway	NULL
.	NULL

Mol	NULL
.	NULL

Car-cinog	NULL
.	NULL

4:339	NULL
.	NULL

17	NULL
.	NULL

Akimoto	NULL
,	NULL
K.	NULL
,	NULL
R.	NULL
Takahashi	NULL
,	NULL
S.	NULL
Moriya	NULL
,	NULL
N.	NULL
Nishioka	NULL
,	NULL
J.	NULL
Takayanagi	NULL
,	NULL
K.	NULL
Kimura	NULL
,	NULL
Y.	NULL
Fukui	NULL
,	NULL
S.	NULL
Osada	NULL
,	NULL
K.	NULL
Mizuno	NULL
,	NULL
S.	NULL
Hirai	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
.	NULL

EGF	NULL
or	NULL
PDGF	NULL
receptors	NULL
activate	NULL
atypical	NULL
PKCA	NULL
through	NULL
phosphatidylinositol	NULL
3-kinase	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

15:788	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

ROLE	NULL
OF	NULL
PKC	NULL
IN	NULL
ACTIVATED	NULL
DRA	NULL
TRANSCRIPTION	NULL
Kraft	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
and	NULL
W.	NULL
B.	NULL
Anderson	NULL
.	NULL

1983	NULL
.	NULL

Phorbol	NULL
esters	NULL
increase	NULL
the	NULL
amount	NULL
of	NULL
Ca**	NULL
,	NULL
phospholipid-dependent	NULL
protein	NULL
kinase	NULL
associated	NULL
with	NULL
plasma	NULL
membrane	NULL
.	NULL

Nature	NULL
301:621	NULL
.	NULL

Ha	NULL
,	NULL
K.-S.	NULL
,	NULL
and	NULL
J.	NULL
H.	NULL
Exton	NULL
.	NULL

1993	NULL
.	NULL

Differential	NULL
translocation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
isozymes	NULL
by	NULL
thrombin	NULL
and	NULL
platelet-derived	NULL
growth	NULL
factor	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
:	NULL
10534	NULL
.	NULL

Asaoka	NULL
,	NULL
Y.	NULL
,	NULL
S.	NULL
Nakamura	NULL
,	NULL
K.	NULL
Yoshida	NULL
,	NULL
and	NULL
Y.	NULL
Nishizuka	NULL
.	NULL

1992	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
,	NULL
calcium	NULL
and	NULL
phospholipid	NULL
degradation	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

17:414	NULL
.	NULL

Monroe	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
J.	NULL
E.	NULL
Niedel	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Cambier	NULL
.	NULL

1984	NULL
.	NULL

B-cell	NULL
activation	NULL
.	NULL

IV	NULL
.	NULL

Induction	NULL
of	NULL
cell	NULL
membrane	NULL
depolarization	NULL
and	NULL
hyper-I-A	NULL
expression	NULL
by	NULL
phorbol	NULL
diesters	NULL
suggests	NULL
a	NULL
role	NULL
for	NULL
protein	NULL
kinase	NULL
C	NULL
in	NULL
murine	NULL
B	NULL
lymphocyte	NULL
activation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

132:1472	NULL
.	NULL

Smith	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
E.	NULL
A.	NULL
Ramsburg	NULL
,	NULL
H.-F.	NULL
Kung	NULL
,	NULL
and	NULL
S.	NULL
K.	NULL
Durum	NULL
.	NULL

1992	NULL
.	NULL

Components	NULL
of	NULL
the	NULL
protein	NULL
kinase	NULL
C	NULL
pathway	NULL
induce	NULL
Ia	NULL
expression	NULL
after	NULL
injection	NULL
into	NULL
macro-phages	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

149:1304	NULL
.	NULL

Setterblad	NULL
,	NULL
N.	NULL
,	NULL
B.	NULL
M.	NULL
Peterlin	NULL
,	NULL
and	NULL
G.	NULL
Andersson	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
role	NULL
of	NULL
the	NULL
X2	NULL
box	NULL
in	NULL
activated	NULL
transcription	NULL
from	NULL
the	NULL
DRA	NULL
promoter	NULL
in	NULL
B-cells	NULL
.	NULL

Immunogenetics	NULL
46:318	NULL
.	NULL

Pulverast	NULL
,	NULL
R.	NULL
J.	NULL
V.	NULL
1964	NULL
.	NULL

Cytology	NULL
of	NULL
Burkitt	NULL
's	NULL
tumour	NULL
(	NULL
African	NULL
lymphoma	NULL
)	NULL
.	NULL

Lancet	NULL
i:238	NULL
.	NULL

Sompayrac	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
and	NULL
K.	NULL
J.	NULL
Danna	NULL
.	NULL

1981	NULL
.	NULL

Efficient	NULL
infection	NULL
of	NULL
monkey	NULL
cells	NULL
with	NULL
DNA	NULL
of	NULL
simian	NULL
virus	NULL
40	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
78:757	NULL
.	NULL

Tsang	NULL
,	NULL
S.	NULL
Y.	NULL
,	NULL
M.	NULL
Nakanishi	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1990	NULL
.	NULL

Mutational	NULL
analysis	NULL
of	NULL
the	NULL
DRA	NULL
promoter	NULL
:	NULL
cis-acting	NULL
sequences	NULL
and	NULL
frans-acting	NULL
factors	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:711	NULL
.	NULL

Voliva	NULL
,	NULL
C.	NULL
F.	NULL
,	NULL
N.	NULL
Jabrane-Ferrat	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
function	NULL
of	NULL
the	NULL
octamer-binding	NULL
site	NULL
in	NULL
the	NULL
DRA	NULL
promoter	NULL
.	NULL

Immunogenetics	NULL
43:20	NULL
.	NULL

Bohm	NULL
,	NULL
S.	NULL
1991	NULL
.	NULL

Identification	NULL
of	NULL
protein-binding	NULL
sequences	NULL
mediating	NULL
constitu-tive	NULL
and	NULL
12-O-tetradecanoylphorbol-13-acetate-induced	NULL
VL30	NULL
transcription	NULL
in	NULL
cultured	NULL
mouse	NULL
and	NULL
human	NULL
keratinocytes	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266:24834	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
G.	NULL
T.	NULL
Merlino	NULL
,	NULL
M.	NULL
C.	NULL
Willingham	NULL
,	NULL
I.	NULL
Pastan	NULL
,	NULL
and	NULL
B.	NULL
H.	NULL
Howard	NULL
.	NULL

1982	NULL
.	NULL

The	NULL
Rous	NULL
sarcoma	NULL
long	NULL
terminal	NULL
repeat	NULL
is	NULL
a	NULL
strong	NULL
promoter	NULL
when	NULL
introduced	NULL
into	NULL
a	NULL
variety	NULL
of	NULL
eukaryotic	NULL
cells	NULL
by	NULL
DNA-mediated	NULL
transfection	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
79:6777	NULL
.	NULL

Baier	NULL
,	NULL
G.	NULL
,	NULL
G.	NULL
Baier-Bitterlich	NULL
,	NULL
N.	NULL
Meller	NULL
,	NULL
K.	NULL
M.	NULL
Coggeshall	NULL
,	NULL
L.	NULL
Giampa	NULL
,	NULL
D.	NULL
Telford	NULL
,	NULL
N.	NULL
Isakov	NULL
,	NULL
and	NULL
A.	NULL
Altman	NULL
.	NULL

1994	NULL
.	NULL

Expression	NULL
and	NULL
biochemical	NULL
characterization	NULL
of	NULL
human	NULL
protein	NULL
kinase	NULL
C-0	NULL
.	NULL

Kur	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

225:195	NULL
.	NULL

Laemmli	NULL
,	NULL
U.K.	NULL
1970	NULL
.	NULL

Cleavage	NULL
of	NULL
structural	NULL
proteins	NULL
during	NULL
the	NULL
assembly	NULL
of	NULL
the	NULL
head	NULL
of	NULL
bacteriophage	NULL
T4	NULL
.	NULL

Nature	NULL
227:680	NULL
.	NULL

Chen	NULL
,	NULL
S.-J	NULL
.	NULL

,	NULL
E.	NULL
Klann	NULL
,	NULL
M.	NULL
C.	NULL
Gower	NULL
,	NULL
C.	NULL
M.	NULL
Powell	NULL
,	NULL
J.	NULL
S.	NULL
Sessoms	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Sweatt	NULL
.	NULL

1993	NULL
.	NULL

Studies	NULL
with	NULL
synthetic	NULL
peptide	NULL
substrates	NULL
derived	NULL
from	NULL
the	NULL
neuronal	NULL
protein	NULL
neurogranin	NULL
reveal	NULL
structural	NULL
determinants	NULL
of	NULL
potency	NULL
and	NULL
selectivity	NULL
for	NULL
protein	NULL
kinase	NULL
C.	NULL
Biochemistry	NULL
32:1032	NULL
.	NULL

Andersson	NULL
,	NULL
G.	NULL
,	NULL
S.	NULL
Pahlman	NULL
,	NULL
V.	NULL
Parrow	NULL
,	NULL
I.	NULL
Johansson	NULL
,	NULL
and	NULL
U.	NULL
Hammerling	NULL
.	NULL

1994	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
human	NULL
NPY	NULL
gene	NULL
during	NULL
neuroblastoma	NULL
cell	NULL
differentiation	NULL
:	NULL
induced	NULL
transcriptional	NULL
activities	NULL
of	NULL
AP-1	NULL
and	NULL
AP-2	NULL
.	NULL

Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

5:27	NULL
.	NULL

Toullec	NULL
,	NULL
D.	NULL
,	NULL
P.	NULL
Pianetti	NULL
,	NULL
H.	NULL
Coste	NULL
,	NULL
P.	NULL
Bellevergue	NULL
,	NULL
T.	NULL
Grand-Perret	NULL
,	NULL
M.	NULL
Ajakane	NULL
,	NULL
V.	NULL
Baudet	NULL
,	NULL
P.	NULL
Boissin	NULL
,	NULL
E.	NULL
Boursier	NULL
,	NULL
F.	NULL
Loriolle	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
bisindolylmaleimide	NULL
GF	NULL
109203X	NULL
%	NULL
is	NULL
a	NULL
potent	NULL
and	NULL
selective	NULL
inhibitor	NULL
of	NULL
protein	NULL
kinase	NULL
C.	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266:15771	NULL
.	NULL

Martiny-Baron	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
G.	NULL
Kazanietz	NULL
,	NULL
H.	NULL
Mischak	NULL
,	NULL
P.	NULL
M.	NULL
Blumberg	NULL
,	NULL
G.	NULL
Kochs	NULL
,	NULL
H.	NULL
Hug	NULL
,	NULL
D.	NULL
Marmé	NULL
,	NULL
and	NULL
C.	NULL
Schiichtele	NULL
.	NULL

1993	NULL
.	NULL

Selective	NULL
inhibition	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
isozymes	NULL
by	NULL
the	NULL
indocarbazole	NULL
GG	NULL
6976	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:9194	NULL
.	NULL

Eissner	NULL
,	NULL
G.	NULL
,	NULL
W.	NULL
Kélch	NULL
,	NULL
H.	NULL
Mischak	NULL
,	NULL
G.	NULL
W.	NULL
Bormkamm	NULL
,	NULL
and	NULL
E.	NULL
Holler	NULL
.	NULL

1994	NULL
.	NULL

Differential	NULL
role	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
in	NULL
cytokine	NULL
induced	NULL
lymphocyte-endothelium	NULL
interaction	NULL
in	NULL
vitro	NULL
.	NULL

Scand	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

40:395	NULL
.	NULL

Brick-Ghannan	NULL
,	NULL
C.	NULL
,	NULL
M.	NULL
L.	NULL
Ericson	NULL
,	NULL
I.	NULL
Schelle	NULL
,	NULL
and	NULL
D.	NULL
Charron	NULL
.	NULL

1994	NULL
.	NULL

Differential	NULL
regulation	NULL
of	NULL
mRNAs	NULL
encoding	NULL
protein	NULL
kinase	NULL
C	NULL
isoenzymes	NULL
in	NULL
activated	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

Hum	NULL
.	NULL

Immunol	NULL
.	NULL

41:216	NULL
.	NULL

Mischak	NULL
,	NULL
H.	NULL
,	NULL
A.	NULL
Bodenteich	NULL
,	NULL
W.	NULL
Kolch	NULL
,	NULL
J.	NULL
Goodnight	NULL
,	NULL
F.	NULL
Hofer	NULL
,	NULL
and	NULL
J.	NULL
F.	NULL
Mushinski	NULL
.	NULL

1991	NULL
.	NULL

Mouse	NULL
protein	NULL
kinase	NULL
C-delta	NULL
,	NULL
the	NULL
major	NULL
isoform	NULL
expressed	NULL
in	NULL
mouse	NULL
hemopoietic	NULL
cells	NULL
:	NULL
sequence	NULL
of	NULL
the	NULL
cDNA	NULL
,	NULL
expression	NULL
patterns	NULL
,	NULL
and	NULL
characterization	NULL
of	NULL
the	NULL
protein	NULL
.	NULL

Biochemistry	NULL
30:7925	NULL
.	NULL

Mischak	NULL
,	NULL
H.	NULL
,	NULL
W.	NULL
Kolch	NULL
,	NULL
J.	NULL
Goodnight	NULL
,	NULL
W.	NULL
F.	NULL
Davidson	NULL
,	NULL
U.	NULL
Rapp	NULL
,	NULL
F.	NULL
Rose-John	NULL
,	NULL
and	NULL
J.	NULL
F.	NULL
Mushinski	NULL
.	NULL

1991	NULL
.	NULL

Expression	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
genes	NULL
in	NULL
hemopoictic	NULL
cells	NULL
is	NULL
cell-type-	NULL
and	NULL
B	NULL
cell-differentiation	NULL
stage	NULL
specific	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

147:3981	NULL
.	NULL

Blobe	NULL
,	NULL
G.	NULL
C.	NULL
,	NULL
W.	NULL
A.	NULL
Khan	NULL
,	NULL
A.	NULL
E.	NULL
Halpern	NULL
,	NULL
L.	NULL
M.	NULL
Obeid	NULL
,	NULL
and	NULL
Y	NULL
.	NULL

A.	NULL
Hannun	NULL
.	NULL

1993	NULL
.	NULL

Selective	NULL
regulation	NULL
of	NULL
expression	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
B	NULL
isoenzymes	NULL
occurs	NULL
via	NULL
alternative	NULL
splicing	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:10627	NULL
.	NULL

Miyazaki	NULL
,	NULL
I.	NULL
,	NULL
R.	NULL
K.	NULL
Cheung	NULL
,	NULL
and	NULL
H.-M.	NULL
Dosch	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
role	NULL
of	NULL
vIL-10	NULL
and	NULL
other	NULL
EBV	NULL
latency	NULL
genes	NULL
carly	NULL
during	NULL
B	NULL
cell	NULL
growth	NULL
transformation	NULL
.	NULL

Semin	NULL
.	NULL

Virol	NULL
.	NULL

5:405	NULL
.	NULL

Tonctti	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
C.	NULL
Henning-Chubb	NULL
,	NULL
D.	NULL
T.	NULL
Yamanishi	NULL
,	NULL
and	NULL
E.	NULL
Huberman	NULL
.	NULL

1994	NULL
.	NULL

Protein	NULL
kinase	NULL
C-	NULL
is	NULL
required	NULL
for	NULL
macrophage	NULL
differentiation	NULL
of	NULL
human	NULL
HL-60	NULL
leukemia	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:23230	NULL
.	NULL

Macfarlane	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
and	NULL
L.	NULL
Manzel	NULL
.	NULL

1994	NULL
.	NULL

Activation	NULL
of	NULL
B-isozyme	NULL
of	NULL
protein	NULL
kinase-C	NULL
(	NULL
PKC	NULL
$	NULL
)	NULL
is	NULL
necessary	NULL
and	NULL
sufficient	NULL
for	NULL
phorbol	NULL
ester-induced	NULL
differentiation	NULL
of	NULL
HL-60	NULL
promyelocytes	NULL
:	NULL
studies	NULL
with	NULL
PKC	NULL
B-defective	NULL
PET	NULL
mutant	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:4327	NULL
.	NULL

Leitges	NULL
,	NULL
M.	NULL
,	NULL
C.	NULL
Schmedt	NULL
,	NULL
R.	NULL
Guinamard	NULL
,	NULL
J.	NULL
Davoust	NULL
,	NULL
S.	NULL
Schaal	NULL
,	NULL
S.	NULL
Stabel	NULL
,	NULL
and	NULL
A.	NULL
Tarakhovsky	NULL
.	NULL

1996	NULL
.	NULL

Immunodeficiency	NULL
in	NULL
protein	NULL
kinase	NULL
C	NULL
B-deficient	NULL
mice	NULL
.	NULL

Science	NULL
273:788	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL

